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CELLULAR EFFECTS OF PLATINUM CHEMOTHERAPEUTICS:
ALTERATIONS BY ANTIDEPRESSANTS AND HEPARAN SULFATE
PROTEOGLYCANS

By Brigitte J Engelmann, B.S.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Chemical Biology at Virginia Commonwealth University.

Virginia Commonwealth University 2012

Major Director: Nicholas P. Farrell/Professor of Chemistry and Director of the Chemical
Biology Ph.D. Program
Co-Director: John J. Ryan/Professor of Biology

The work discussed here is divided into two projects. The first project involves the
interactions between antidepressants and the platinum based chemotherapeutics while

xvi
the second project begins to investigate possible implications of a recently discovered
uptake mechanism for positively charged platinum drugs.

Gaining understanding of the interactions between antidepressants and platinum-based
chemotherapeutics is important due to the frequency with which they are prescribed
together. Although using a combination regimen of antineoplastics is beneficial to the
patient, not all drug interactions are. For instance, many of the serotonin reuptake
inhibitors have been shown to decrease the efficacy of tamoxifen.

Desipramine, a tricyclic antidepressant used to treat neuropathic pain, has been shown
to increase the cytotoxicity of cisplatin, oxaliplatin and carboplatin in the human colon
carcinoma cell line, HCT116 wt. To study this interaction, the cell line specificity as well
as the drug specificity with regard to both the platinum-based chemotherapeutic and the
antidepressant were investigated. The data show that the effect is both cell line specific
as well as drug specific with respect to both types of drugs.

To elucidate the mechanism behind the alteration in cytotoxicity of the platinum drugs,
the effect of p53 status was investigated. A reduction of the effect is observed in the
absence of p53, suggesting that there is a p53 dependent mechanism as well as a p53
independent mechanism. The tricyclic antidepressants and fluoxetine are known to be
calmodulin inhibitors. Calmodulin inhibition mirrored some of the effects seen with the
antidepressants suggesting that calmodulin inhibition might also play a role in the
mechanism.

xvii

The second project is based on the discovery that heparan sulfate proteoglycans
mediate the uptake of positively charged platinum complexes. Heparan sulfate
proteoglycans are important in cell-cell as well as cell-extracellular matrix adhesion. In
cancer, heparanase, the enzyme that cleaves heparan sulfate, is over expressed
creating a pro-angiogenic and pro-metastatic state. This work demonstrates that the
positively charged platinum complexes can inhibit heparanase activity by binding to the
substrate (heparan sulfate proteoglycans). This suggests that this class of drugs may
have the capacity to be anti-angiogenic and anti-metastatic as well as cytotoxic.

Chapter 1: Introduction

1.1 Cancer
Cancer is not a single disease. Instead, the word cancer refers to a group of diseases
that are characterized by uncontrolled growth of abnormal cells. The abnormal cells
spread throughout the body and this can result in death. In fact, in the United States,
cancer is the cause of almost 25% of all deaths. This makes cancer the second most
common cause of death in the United States. It is second only to heart disease.1
Although cancer is second to heart disease in the annual number of deaths, heart
disease is second to cancer in years of potential life lost.2

The American Cancer Society estimates that this year in the United States, 1,638,910
new cancer cases will be diagnosed and 577,190 people will die from cancer.1 The
individual and societal financial burdens due to cancer are enormous. According to the
NIH Fact Book Fiscal Year 2011, in 2008, the direct cost in medical care for cancer
patients was 77.4 billion dollars. This includes costs for doctors’ visits and hospital
stays, prescribed medications and home care but excludes costs associated with
nursing home care. The NIH further estimates the indirect cost of mortality to be 124
billion dollars. This is an estimate of the cost of loss of productivity due to premature

1

death. In total, cancer cost the United States 201.4 billion dollars in 2008. This is
second only to the costs associated with heart disease.2

Although cancer refers to many diseases, there are certain traits that are consistent
across them all.

Malignant tumors are poorly differentiated (the tissue no longer

resembles the parent tissue), monoclonal (derive from a single cell), the growth rate is
often increased and the nuclear:cytoplasmic ratio is increased compared to benign
tumors or normal tissue. Malignant tumors are also able to locally invade tissue as well
as metastasize to distant tissues.3

It is thought that tumorigenesis is a multi-step process that reflects genetic alterations.
Hanahan and Weinberg suggest that there are six alterations in cell physiology that are
necessary for malignant tumorigenesis.

These alterations are 1) self-sufficiency in

growth signals, 2) insensitivity to growth-inhibitory signals, 3) the ability to evade
apoptosis, 4) the ability to replicate and divide forever, 5) sustained angiogenesis, and
6) the ability to invade tissues and metastasize.4

Cancer is usually treated with a combination of surgery, radiation, immunotherapy and
chemotherapy. An example of immunotherapy is the use of Rituximab in the treatment
of non-Hodgkin’s lymphoma.

Rituximab is a monoclonal antibody that binds to a

surface protein on the lymphoma cells and leads to cell death.5 Chemotherapy is the
treatment of cancer with cellular toxins. Examples of chemotherapeutic agents are the
platinum-based chemotherapeutics: cisplatin, oxaliplatin and carboplatin (Figure 1.1).

2

H3N

Cl

H2
N

Pt
H3N

O

O

Pt

Cl
Cisplatin

N
H2

O

Oxaliplatin

O

Carboplatin

Figure 1.1 Structures of platinum-based chemotherapeutics used clinically.

1.2 Platinum Drugs
1.2.1 Cisplatin, Oxaliplatin and Carboplatin
Cisplatin was discovered in 1845 by Michel Peyrone. Despite its early discovery, its
anticancer properties were not discovered until the 1960s. It was then that Barnett
Rosenberg discovered that cisplatin caused the elongation of Escherichia coli (E. coli)
cells by inhibiting cellular division. It was due to this observation that cisplatin was
tested for its anticancer properties.6 In 1978, it was approved by the FDA.7 Today,
cisplatin is used to treat ovarian, bladder, cervical and head and neck cancers as well
as melanoma and lymphomas.6

In fact, cisplatin in combination with other

chemotherapeutic agents cures over 90% of testicular cancer cases.8

It is generally believed that the cytotoxic activity of cisplatin and the other platinumbased chemotherapeutics is due to their interactions with DNA leading to apoptosis.
Cisplatin is usually administered to the patient intravenously.

The chloride

concentration in the plasma is quite high (approximately 100 mM).

This is a high

enough concentration that it will limit the replacement of the chloride ligands by water

3

molecules.

Although hydrolysis of the chloride ligand is inhibited, cisplatin is still

reactive and binds to albumin in the plasma.9 This binding is quite extensive and is
thought to deactivate the cisplatin.6 In fact, it has been reported that one day after
cisplatin intravenous infusion, 65-98% of the platinum in the plasma is bound to
albumin. This binding is irreversible.9 Any remaining intact cisplatin is able to enter the
cells where there is a much lower chloride concentration (approximately 4 mM).
Hydrolysis of the chloride ligand then occurs and the cisplatin is able to bind to the DNA
at adjacent guanines on the same strand of DNA (intrastrand adduct) or at two guanines
one on each strand of the DNA double helix (interstrand adduct). The cell will then
either proceed to apoptosis or the platinum-DNA lesion will be repaired and the cell will
continue living.6 As shown in Figure 1.2. The limiting toxicity of cisplatin is neurotoxicity
resulting in peripheral neuritis, tinnitus and hearing loss.

Cisplatin is also quite

nephrotoxic.10

Since the discovery of cisplatin, two other platinum-based chemotherapeutics have
been added to clinical use: carboplatin and oxaliplatin (Figure 1.1).

Carboplatin is

administered intravenously.11 It is less toxic than cisplatin and causes much less neuroand nephro-toxicity.10, 11,12 The lower toxicity allows it to be given in a higher dose, but
unfortunately, it is active in the same range of tumors as cisplatin.11 The limiting toxicity
of carboplatin is myelosupression.10,
cancer.10,13

12

Oxaliplatin is used in advanced colon

It has less nephrotoxicity and myelosuppression than cisplatin and

carboplatin, but its dose limiting toxicity is peripheral sensory neuropathy.10,12 Patients
reported dysaesthesias of the arms, legs, mouth and throat.

4

In one patient the

dysaesthesia of the throat was accompanied by laryngospasm (a spasmodic closing of
the larynx which results in the inability to get air into the lungs). Other patients reported
ataxia (loss of coordination) and gait disturbances. Although these side effects are
disturbing, patients often experience complete recovery after stopping oxaliplatin
therapy.

This is a distinct advantage over cisplatin where the neuropathy may be

permanent.12

Figure 1.2 The cytotoxic pathway for cisplatin. Once cisplatin enters the cell, the chloride ligands are
replaced with aqua groups. Cisplatin is then able to bind to the DNA. If the cell cannot repair the DNA
damage, the cell will proceed to apoptosis down path a). If the DNA can be repaired, the cell will
proceed down path b). This figure was taken from Alderden RA, Hall MD, and Hambley TW, (2006) J
Chem Ed 83:728-734.
5

1.2.2 Polynuclear Platinum Compounds
In an effort to circumvent resistance against cisplatin and its analogues, researchers
developed platinum-based compounds that form very different platinum-DNA adducts.
To this end, researchers have developed multinuclear platinum complexes that are
connected with linkers.11 An example of this type of drug is BBR3464 (Figure 1.3), a
trinuclear platinum complex where the platinum coordination units are linked by
alkanediamine linkers.14

BBR3464 has been shown to have increased cellular

accumulation compared to cisplatin in the osteosarcoma cell lines U2-OS and U2OS/Pt.14 It has also been shown to be more cytotoxic than cisplatin and to be effective
in the treatment of cisplatin-resistant cell lines and tumors in vitro as well as in vivo.14, 15

While BBR3464 covalently binds to DNA, the trinuclear platinum chemotherapeutics
AH44 and AH78 (Figure 1.3) non-covalently bind to DNA. In the case of AH44 and
AH78, the reactive chloride ligands of BBR3464 are replaced with inert ammonia or
amine groups.16, 17

6

H3N

NH2(CH2)6H2N
Pt

X

NH3
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Pt
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Pt
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BBR3464 X=Cl;

n= 4

AH44

X=NH3;

n=6
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X=NH2(CH2)6NH2;

n=8

NH3

Figure 1.3 Structures of the polynuclear platinum complexes BBR3464, AH44 and AH78.

1.3 Factors Affecting Cytotoxicity
There are three major factors that affect the cytotoxicity of the platinum drugs. The first
factor is the nature of the platinum-DNA adducts formed and the frequency with which
these adducts are formed. The second factor is deactivation of the platinum drugs by
reactions with sulfur-containing nucleophiles such as glutathione. The third factor is
alteration of the cellular uptake and efflux of the platinum drugs.

1.3.1 Platinum-DNA Adducts
Cisplatin can form monofunctional and bifunctional adducts to DNA (Figure 1.4).7,

18

The majority of adducts formed are 1,2 intrastrand adducts at adjacent guanines.
Cisplatin also forms 1,2-intrastrand adducts between an adenine and a guanine as well
as 1,3-intrastrand adducts between two guanines with another base in between the two

7

guanines.

Cisplatin is also able to form 1,2-interstrands adducts between two

guanines.18, 19

A

C

B

Monofunctional Adduct

Interstrand Adduct

Intrastrand Adducts

Figure 1.4 Representations of cisplatin-DNA adducts. From: Fichtinger-Schepman AJ, van der Veer JL,
den Harto g JHJ, Lohman PHM, Reedijk J. Biochemistry 1985, 24:707-713

BBR3464 forms long range 1,4 and 1,6-interstrand cross-links.20,

21, 22

The non-

covalently binding platinum drugs, AH44 and AH78, have two unique DNA binding
features, backbone tracking and minor groove spanning.17

Backbone tracking

describes the electrostatic interactions between the non-covalently binding platinum
drugs and the phosphate oxygen atoms of the DNA backbone. Minor groove spanning
describes how the non-covalently binding platinum drugs can interact with two
phosphate oxygens on different DNA strands via two phosphate clamps thereby
spanning the minor groove of the DNA duplex.17

The different types of platinum-DNA adducts formed by these drugs are not treated the
same way by the cells. For instance, the high mobility group (HMG) proteins recognize
8

cisplatin-DNA adducts. It is thought that this may modulate the cytotoxicity of cisplatin
in two ways. First, many HMG proteins are transcription factors and if they are binding
to cisplatin-DNA adducts, they are not binding to their normal binding sites. This would
disrupt cellular function.7 Second, the HMG proteins may actually shield the cisplatinDNA adducts from damage recognition resulting in a reduction of cisplatin-DNA adduct
repair.7 The BBR3464-DNA adducts are not recognized by the HMG proteins.22

These platinum-DNA adducts cause DNA damage which initiates biochemical signaling
pathways.23 The platinum-DNA adducts can activate p53 which can lead to cell cycle
arrest. Once the cell is arrested, the cell can either repair the DNA damage or proceed
to apoptosis.7

1.3.2 Deactivation of the Platinum Drugs
Although DNA is thought to be the cytotoxic target of the platinum based
chemotherapeutics, they are also able to bind to sulfur-containing molecules.
examples

of

sulfur-containing

molecules

that

bind

to

the

platinum

Two
based

chemotherapeutics are human serum albumin and glutathione.6, 9, 24 When the platinum
drugs bind to these sulfur-containing molecules, the platinum drugs are deactivated and
are no longer able to bind to their DNA target. An increased cellular level of glutathione
is an important resistance mechanism that has been observed in many platinumresistant cell lines.25

9

1.3.3 Cellular Uptake and Efflux of Platinum-Based Chemotherapeutics
Some resistant cell lines have been shown to have decreased accumulation of the
platinum drugs when compared to their platinum-sensitive counterparts. Resistance to
cisplatin and the other platinum-based chemotherapeutics is a frequent reason for
treatment failure. Platinum-resistance may be intrinsic to the cell or tissue type or it may
be acquired through exposure to the drug over time, during treatment for instance.7
Differences in accumulation are either caused by changes in platinum uptake or by
changes in platinum efflux.

1.3.3a Role of CTR1 in Platinum Drug Uptake
While early experiments suggested that cisplatin and its analogues entered cells by
passive diffusion, later studies suggested that these platinum based chemotherapeutics
likely use transporters as well as passive diffusion to enter the cell.25 CTR1 (copper
transporter 1) is a copper influx transporter that also transports platinum based
chemotherapeutics.25 Holzer et al. investigated the role of human CTR1 on cisplatin
accumulation in human ovarian carcinoma cells. A2780 cells were either transfected
with an empty vector or with a vector containing the human CTR1 cDNA. Interestingly,
although the human CTR1 increased cisplatin accumulation there was only a marginal
increase in cytotoxicity.26

Kabolizadeh et al. also investigated the role of human CTR1 in cisplatin and BBR3464
mediated apoptosis in A2780 cells and A2780 cells that were transfected with a vector
containing the human CTR1 cDNA. In this study, the expression of human CTR1 gave
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increased accumulation of cisplatin and BBR3464 as well as increased cytotoxicity for
both of the platinum drugs.27

Beretta et al. studied the role of human CTR1 in the cisplatin-resistant cervix squamous
cell carcinoma A431/Pt. In contrast to the studies discussed above, A431/Pt cells that
were transfected with human CTR1 did not show changes in platinum accumulation
when compared to A431/Pt cells that were not overexpressing human CTR1.
Furthermore, no alteration in cisplatin sensitivity was observed in the A431/Pt cells that
overexpressed human CTR1 compared to the A431/Pt cells that were not
overexpressing human CTR1.28

1.3.3b Organic Cation Transporters
The organic cation transporters are transmembrane transporters that are members of
the SLC22A family. There are three organic cation transporters known as OCT1, 2 and
3.25

OCT1 is primarily expressed on the basolateral membrane of hepatocytes.29

OCT2 is primarily expressed in the kidney25 while OCT3 is expressed in many tissues
including the kidney, liver, placenta, skeletal muscle and heart.25, 29 These transporters
transport drugs, endogenous metabolites and toxins and have been shown to be
important in cellular accumulation of platinum based chemotherapeutics.30 Cisplatin
has been shown to be transported by OCT2 while oxaliplatin has been shown to be
transported by OCT1, 2 and 3.31 Carboplatin has not been shown to be a substrate for
the organic cation transporters. In fact, it has been shown that the transport of cisplatin
by OCT2 is responsible for the nephrotoxicity observed during cisplatin therapy.30 It is
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interesting to note however, that although oxaliplatin is also transported by OCT2,
nephrotoxicity was not observed with oxaliplatin.30 The fact that OCT1 and OCT2 are
expressed in a variety of colon cancer cell lines may explain why oxaliplatin is more
effective in treating colon cancer than cisplatin.23

1.3.3c Heparan Sulfate Proteoglycans
Heparan sulfate proteoglycans have been shown to mediate cell entry for positively
charged tri-platinum compounds.32

Due to the fact that nonaarginine is the most

efficiently transported ‘protein transduction domain’33, Silva et al. used a TAMRA (5(and 6-) carboxytetramethylrhodamine) tagged nonaarginine to investigate how different
platinum drugs competed with the nonaarginine for cellular internalization in wild type
CHO cells. The neutral platinum compounds cisplatin and oxaliplatin did not inhibit the
internalization of the nonaarginine.

However, the positively charged tri-platinum

compounds BBR3464, AH44 and Triplatin NC (aka AH78) prevented internalization of
the nonaarginine in a charge-dependent manner. BBR3464 with a charge of +4 and
AH44 with a charge of +6 decreased the nonaarginine internalization while Triplatin NC
with a charge of +8 completely inhibited internalization of the nonaarginine. This was
also examined in two cancer cell lines: the human colon carcinoma HCT116 and the
osteosarcoma SAOS-2. Interestingly, the positively charged tri-platinum drugs showed
increased inhibition of nonaarginine internalization in the tumor cell lines compared to
the normal CHO cells.

This suggests that these drugs may have some tumor

selectivity. To confirm that heparan sulfate proteoglycans were responsible for these
observations, Silva et al. investigated the cellular accumulation of the platinum drugs in
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CHO cells, heparan-sulfate deficient CHO cells and heparan- and chondroitin-sulfate
deficient CHO cells. The cellular accumulation of BBR3464, AH44 and Triplatin NC was
reduced in the CHO mutants confirming the role of proteoglycans in the uptake of
positively charged platinum drugs.32

Furthermore, endocytosis is known to be a

mechanism of cell entry for heparan sulfate proteoglycans.32 Silva et al. demonstrated
that macropinocytosis, a type of endocytosis, is responsible for the uptake of Triplatin
NC and to a lesser extent BBR3464.32

1.3.3d ATP7A and ATP7B Copper Efflux Transporters
ATP7A and ATP7B are copper efflux transporters that have been shown to have a role
in platinum drug resistance. Although ATP7A and ATP7B are very similar proteins, they
are expressed in different tissues. ATP7A is expressed in the intestines while ATP7B is
expressed in the liver and kidney.25 ATP7B expression is a poor prognostic factor for
chemotherapy success in patients with solid carcinomas.25

Samimi et al. transfected Me32a fibroblast cells to express either ATP7A or ATP7B.
The Me32a cell line does not normally express ATP7A or ATP7B. The expression of
ATP7A or ATP7B resulted in resistance to cisplatin and carboplatin. Surprisingly, the
resistance was also accompanied by an increase in platinum cellular accumulation but
not an increase in platinum-DNA binding. Increased levels of platinum were measured
in vesicles suggesting that ATP7A and ATP7B could sequester the cisplatin and
carboplatin into vesicles but that they could not re-localize to the cell membrane and
efflux the platinum drugs.34 Interestingly, although ATP7A and ATP7B increased the
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cellular accumulation of oxaliplatin, the cells became more sensitive to oxaliplatin as
opposed to more resistant as was observed with cisplatin and carboplatin.

The cells

expressing ATP7A did not have increased oxaliplatin in vesicles when compared to the
parental cell line, but they did show increased oxaliplatin-DNA binding.

The cells

expressing ATP7B showed increased levels of oxaliplatin in the vesicles as well as
increased oxaliplatin-DNA binding when compared to the parental cell line.

This

demonstrates that oxaliplatin is not as efficiently sequestered by ATP7A as it is by
ATP7B.

Samimi et al. suggest that although ATP7B can sequester oxaliplatin, the

sequestration does not inactivate the oxaliplatin. This was supported by the observed
increase in oxaliplatin-DNA binding in cells expressing ATP7B.34

In contrast, Katano et al. observed that in cisplatin-resistant cells that were cross
resistant to copper, platinum accumulation was reduced compared to the platinum
sensitive parental lines. The resistant ovarian carcinoma cell lines used, A2780/CP,
2008/C13*5.25 and IGROV-1/CP, all exhibited increased levels of the copper efflux
transporters when compared to their parental cell lines. A2780/CP and 2008/C13*5.25
overexpressed ATP7A. IGROV-1/CP overexpressed ATP7B. The 2008/C13*5.25 cell
line also showed increased copper and platinum efflux compared to the 2008 parental
cell line.35

Taken together, these data show that the copper efflux transporters, ATP7A and ATP7B
are important in platinum resistance.

They have been shown to decrease the

cytotoxicity of platinum drugs by either sequestering the drugs into vesicles so that they
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are unable to reach their DNA target or by decreasing the cellular accumulation of the
platinum drugs.

1.4 Doctoral Projects
This thesis describes two projects that are the result of different platinum cellular
accumulation pathways and the implications of these pathways.
addresses

the

interactions

between

antidepressants

and

The first project,
platinum-based

chemotherapeutics. This project began with the hypothesis that desipramine, a tricyclic
antidepressant and known organic cation transporter inhibitor36, might inhibit the effects
of cisplatin, oxaliplatin and the experimental positively charged platinum drug BBR3464.
Not only did desipramine fail to block cellular accumulation of all three platinum drugs,
but it also increased the cytotoxicity of cisplatin, oxaliplatin and BBR3464.37 Chapters 2
and 3 examine potential mechanisms to explain the observed augmentation in
cytotoxicity of the platinum drugs. They also address how cell specific and drug specific
the observed interactions are.

Chapter 2 has been published in the Journal of

Biological Inorganic Chemistry.37

The second project began with the hypothesis that positively charged platinum-based
chemotherapeutics bind to heparan sulfate proteoglycans on the cell surface and use
this interaction as a mechanism for cellular uptake. This new uptake mechanism was
demonstrated by Silva et al.32 Chapter 4 addresses the role of glycosaminoglycans and
proteoglycans in both normal and pathological states. It also investigates the potential
implications of platinum drug binding to heparan sulfate in cancer treatment.
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Chapter 2: Platinum Anti-Cancer Agents
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This is a version of work that was subsequently published in the Journal of Biological
Inorganic Chemistry. J Biol Inorg Chem, 2012, 17(1): 123-132

2.1 Abstract
A unique potentiation of platinum drug cytotoxicity is noted in the presence of the
tricyclic antidepressant desipramine. Desipramine is used for treating neuropathic pain,
particularly in prostate cancer patients. The clinically used drugs cisplatin (cis[PtCl2(NH3)2],

c-DDP),

oxaliplatin

(1,2-diaminocyclohexaneoxalatoplatinum(II),
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[Pt(ox)dach)]) and the cationic trinuclear agent BBR3464 [{trans-PtCl(NH3)2}2µ-(transPt(NH3)2(H2N(CH2)6NH2)2)]4+, which has undergone evaluation in Phase II for activity in
lung and ovarian cancers, were evaluated. Surprisingly, desipramine greatly augments
the cytotoxicity of all the platinum-based chemotherapeutics in the HCT116 colorectal
carcinoma cell line. Desipramine enhanced cellular accumulation of cisplatin, but had no
effect on the accumulation of oxaliplatin or BBR3464, suggesting that enhanced
accumulation could not be a consistent means by which desipramine altered the
platinum drug-mediated cytotoxicity.

The enhancement of cytotoxicity due to

desipramine resulted in increased expression of p53, mitochondrial damage, caspase
activation and PARP cleavage. The study shows that desipramine may be a means of
enhancing chemo-responsiveness of platinum drugs and the results warrant further
investigation.

The results emphasize the importance of understanding the differential

pharmacology of adjuvants employed in combinations with cancer chemotherapeutics.

2.2 Introduction
Cancer chemotherapy usually involves treatment with drug combination regimens.
Platinum-based drugs play an important part as components of these regimens.
Cisplatin is curative in testicular cancer while oxaliplatin (Eloxatin) is recommended with
5-fluorouracil (FOLFOX) for treatment of metastatic colon cancer. The pharmacological
action of any drug must be monitored in light of proposed combinations. The
pharmacological parameters affecting platinum drug cytotoxicity and antitumor activity
are generally accepted to be (i) the nature and extent of target (DNA) binding; (ii) the
extent of platinum drug cellular accumulation and (iii) metabolizing (destabilizing)

21

interactions with sulfur-containing biomolecules such as Human Serum Albumin (HSA)
and glutathione (GSH). Reduced cellular accumulation is consistently being seen as a
major cause of development of clinical resistance.1,

2

Cellular accumulation can be

affected by drug combinations and this point may be an important feature in designing
potential combination regimens for new, emerging agents. In pre-clinical studies, the
Raf kinase inhibitor BAY43-9006 reduces cellular accumulation of cisplatin and
oxaliplatin3 whereas, in contrast, the 20S proteasome inhibitor Bortezomib enhances
cisplatin accumulation by blocking the cisplatin-induced down-regulation of the hCTR1
transporter in a concentration-dependent manner.4

Interestingly, the concomitant

administration of imatinib with cisplatin prevents cisplatin-induced nephrotoxicity by
inhibiting cisplatin renal accumulation.5

Adjuvant therapy with antidepressants is also common standard of care for cancer
patients.6 People with cancer are three times more likely than the general population
and almost two times more likely than other hospitalized medical patients to develop
major depression.7 Untreated, this can lead to decreased compliance with medical care
as well as increasing the psychological toll on patient and family. Patients will also most
likely be treated with combination chemotherapy with a variety of anticancer drugs.
There is therefore an important need to examine how the combination of an adjuvant
drug interacts with the chemotherapeutic agents - the combination may be additive or
antagonistic, where the drug interference can result in decreased efficacy of the
treatment. Recent discussion on the negative effect of antidepressants on tamoxifen
therapy in breast cancer patients highlights the necessity to understand the
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pharmacology of drug combinations.8, 9 The differential effects noted above on cellular
platinum accumulation, and hence efficacy, could also extend to adjuvant therapies.

The choice of a specific antidepressant depends on a number of factors including the
nature of the depressive symptoms, medical problems present, and side effects of the
specific drug. Low doses of tricyclic antidepressants can be especially useful as
adjuvant pain medications in patients with neuropathic pain syndromes. Desipramine
(Figure 2.1), is one such tricyclic and is important for treating neuropathic pain from
cancer chemotherapy.10, 11 It is also relevant as an inhibitor of organic cation transport
accumulation pathways, a possible mechanism for cellular accumulation of cisplatin.1, 12
As such, it was anticipated that desipramine might antagonize the effects of cisplatin
and oxaliplatin, Figure 2.1, and their side effects of nephrotoxicity and neuropathy
respectively.13 The tumor cell line selected for study was human colon HCT116. We
also examined the pre-clinical drug BBR3464 because a survey of cytotoxicity across
the NCI tumor panel showed enhanced sensitivity of colon cancers to this drug.14 This
work demonstrates the role of desipramine in modulating the biological effects of
platinum drugs and the unexpected potentiation of cytotoxicity in the presence of the
antidepressant.
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Figure 2.1 Structures of desipramine and the platinum compounds studied for cellular effects in the
presence of desipramine.

2.3 Materials and Methods
2.3.1 Compound Synthesis
BBR3464 and cisplatin were synthesized as previously described.15 Oxaliplatin and
desipramine were obtained from Sigma-Aldrich (St. Louis, MO).

2.3.2 Cell Culture Conditions
The colorectal carcinoma cell lines HCT116 were the kind gift of Professor Bert
Vogelstein (Johns-Hopkins University, Baltimore, MD). HCT116 cells were cultured with
24

RPMI 1640 with 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin,
100 µg/mL streptomycin, and 1 mmol/L sodium pyruvate (cRPMI, all from Biofluids,
Rockville, MD) in humidified air with 5% CO2. For the assays, cells were cultured in 6well plates at an initial density of 7.0 × 104 cells/mL. Different concentrations of drugs
were added to each well as indicated. Total cells (adherent and non-adherent cells)
were collected. BBR3464, c-DDP, and oxaliplatin concentrations were adjusted to
achieve approximately 30%-40% apoptosis after 72 hours of treatment, allowing
measurement of enhancement or inhibition in presence of the antidepressant.

2.3.3 Propidium Iodide DNA Staining and Analysis of Apoptosis
Samples were fixed in a solution containing 35% 1x PBS (vol/vol), 12.48% fetal bovine
serum (vol/vol), and 52.52% 70% ethanol (vol/vol). The samples were then washed
with phosphate buffered saline (PBS), and stained with a solution containing 94% 1x
PBS (vol/vol), 0.1 mg/mL RNase A, 0.0001 M EDTA, and 0.04 mg/mL propidium iodide
(PI).

The samples were stained for two hours.

Samples were then analyzed for

subdiploid DNA content using a FACScan flow cytometer (BD Biosciences, San Jose,
CA). It is noteworthy that this protocol differs significantly from the more common PIbased exclusion, which only differentiates live versus dead cells. Through fixation and
RNase A treatment, we were able to detect intact versus fragmented DNA, revealing
discrete stages of the cell cycle and the percentage of the population undergoing
apoptosis.
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2.3.4 Assessment of Mitochondrial Membrane Potential
Alteration in mitochondrial membrane potential was assessed by staining with 3,3’ –
dihexyloxacarbocyanine iodide [Di(OC6)3]; Molecular Probes, Eugene, OR]. Di(OC6)3
was added to 200 µL of cells at 40 nmol/L final concentration. Cultures were incubated
for 30 minutes at 37oC in a CO2 incubator. The cells were then washed twice with PBS
and resuspended in 200 µL PBS for flow cytometric analysis using a forward and side
scatter gate sufficiently open to include apoptotic/dying cells.

2.3.5 Assessment of Caspase Activation
Staining for active caspases was performed with caspase kits (Immunochemistry
Technologies, LLC, Bloomington, MN), as specified by the manufacturer. Cells were
incubated with a cleavable substrate that binds to the active caspases-3 and -7.
Subsequent substrate cleavage results in increased fluorescence intensity, interpreted
as caspase-positive cells. The percentage of caspase-positive cells was measured by
flow cytometry.

2.3.6 Platinum Accumulation Assays
Cells were plated at 2.0×106 cells/mL. Platinum drug was added in different
concentrations alone or 60 minutes after the addition of desipramine. After 8 or 16
hours, cells were harvested and washed twice with PBS. The cell pellets were then
dissolved in hot nitric acid followed by the addition of hydrogen peroxide and
hydrochloric acid, according to the United States Environmental Protection Agency
procedure 3050b (all volumes reduced by 1/10) and diluted with Milli-Q water (Millipore
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Corporation, Billerica, MA).

Platinum analysis was performed on a Vista-MPX

simultaneous inductively coupled plasma optical emission spectroscopy (ICP-OES) at
265 nm (Varian Inc., Palo Alto, CA). Standards and blank were prepared the same as
the samples.

2.3.7 Platinum Drug Binding to Human Serum Albumin
A stock solution containing 0.33 mM human serum albumin (HSA) was prepared in
phosphate buffered saline (PBS).

Individual 1 mM stock solutions of cisplatin,

oxaliplatin, BBR3464, and desipramine were also prepared in phosphate buffered saline
(PBS). Final sample solutions contained the platinum drugs, desipramine and HSA in a
stoichiometric 3:3:1 platinum drug:desipramine:HSA ratio.

Final control solutions

contained the platinum drugs and HSA in a stoichiometric 3:1 platinum drug:HSA ratio.
To keep the volume of the controls the same as the samples, the volume of
desipramine was replaced with an equal volume of PBS.

These samples were

prepared by adding desipramine or PBS to the HSA solution and allowing the resulting
solution to incubate for 1 hour at 37˚C. The platinum drugs were then added and 150
μL aliquots were taken at 0 minutes, 30 minutes, 2 hours, 6 hours, 24 hours and 48
hours. The samples were pipetted into filter tubes and centrifuged for 10 minutes at
14000 rpm. The liquid that came through the filter was the free drug portion. The filter
was then flipped over; placed in another tube and centrifuged at 1000 rpm for 5 minutes
to give the portion with drug-bound protein. After the samples were centrifuged, all
portions were then digested with acid according to the United States Environmental
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Protection Agency procedure 3050b (all volumes reduced by 1/10) as described
previously15 and analyzed using ICP-OES.
2.3.8 Measurement of Platinum Accumulation in DNA
Cells were plated at 2.0×106 cells/mL. Platinum drug was added in 160 µM
concentrations alone or 60 minutes after the addition of desipramine. After 36 hours
cells were harvested and washed twice with PBS. The DNA was extracted using a
DNeasy Blood and Tissue kit (Qiagen, Valencia, CA) according to manufacturer’s
instructions. The concentration and the purity of the extracted DNA were calculated
using a Nanodrop spectrophotometer and the 260/280nm absorbance ratio.

The

samples were then digested with acid according to the United States Environmental
Protection Agency procedure 3050b (all volumes reduced by 1/10) and analyzed using
a Varian 820-MS Axial Simultaneous inductively coupled mass spectrometer (Varian,
Palo Alto, CA).

2.3.9 Western Blotting
Whole-cell lysates were blotted with a mouse monoclonal antibody against human p53
(BD Bioscience), monoclonal antibody against poly-ADP ribose polymerase (PARP)
(Trevigen, Inc.), mouse monoclonal antibody against ERK (Cell Signaling Technology),
and, subsequently resolved with secondary antibody conjugated with horseradish
peroxidase.

Blots were then treated with a chemiluminescent substrate (Pierce,

Rockford, IL, USA) and exposed to film. Band intensity was measured by densitometry
with an Eagle Eye II system (Stratagene, La Jolla, CA).
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2.3.10 Colony Formation Assay
Cells were cultured (250-1500 cells per well in a 6 well plate) and 12 hours after plating,
cells were treated with drugs for 48 hours. Afterward, the drug containing media was
carefully removed, the cells were washed once, and fresh media lacking drugs was
added. Colony formation assays were cultured for an additional 10-14 days after which
the media was removed, and the cells were fixed with methanol, stained with crystal
violet and counted manually.

2.3.11 Statistical Analysis
Statistical analysis was performed using t-test for two data points using SysStat9
software (SPSS, Chicago, IL, USA). p < 0.05 was considered to be significant.

2.4 Results
2.4.1 Effect of Desipramine on Platinum Drug-Induced Cytotoxicity. Potentiating
Effects of Desipramine.
Desipramine surprisingly augmented cytotoxicity of all three platinum drugs studied
(Figure 2.2). The enhancement of apoptosis in the presence of desipramine is time and
concentration-dependent. The highest percent apoptosis was observed at a
desipramine concentration of 20 µmol/L in combination with BBR3464 or c-DDP but for
oxaliplatin, the percent apoptosis peaked with 40 µmol/L desipramine. At this latter
concentration, desipramine alone has very little effect on HCT116 survival and this
concentration was therefore used for time-dependence studies. To determine
concentration-dependence, cells were treated with platinum drugs and different
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concentrations of desipramine for 72 hours, and percent apoptosis was measured by
PI-DNA staining. Concentrations of the platinum drugs were chosen to give
approximately 30-40% apoptosis as single agents after 72 hours. In the case of
cisplatin, the enhancement reached a maximum at 48 hours after treatment, where
desipramine increased the c-DDP-induced apoptosis from 27% to approx. 80% (Figure
2.2A). For oxaliplatin, a quantitatively smaller but significant increase in apoptosis from
49% to 76% was observed after 72 hours of treatment in the presence of the
antidepressant (Figure 2.2B). The BBR3464-desipramine combination at 72 hours also
showed a significant increase to approximately 80% in comparison to that induced by
either desipramine or BBR3464 alone.

2.4.2 Mechanistic Studies on the Effect of Desipramine on Platinum Drug Cellular
Accumulation and DNA Binding.
To examine the possible mechanism(s) of the desipramine effect, several assays were
employed including measurement of HSA interactions, total cellular platinum
accumulation and platinum-DNA binding, as well as the effects of the platinum
drug/antidepressant combination on downstream signaling pathways.
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Figure 2.2 Time course dependence of the effect of desipramine on platinum-drug-induced apoptosis in
HCT116 colorectal carcinoma cells. Sub-diploid cell content was detected by PI-DNA staining. In A, B, C,
HCT116 cells were cultured with 10 µmol/L c-DDP, 30 µmol/L oxaliplatin or 50 µmol/L BBR3464, respectively
for the indicated time points in the absence and presence of 40 µmol/L desipramine. Platinum-drug
concentrations were adjusted to achieve approximately 20-30% apoptosis after 48h, allowing measurement of
enhancement or inhibition. Platinum drugs were added to the media after 1h of treatment with desipramine.
Each point represents the average (+/- SEM) of three independent experiments. *, p<0.05 when comparing
cells treated with and without desipramine, by Student’s t-test. All points after 48h have p <0.05 for Pt drug
with desipramine vs platinum drug alone
31

2.4.2a Interactions with Human Serum Albumin
Serotonin-specific reuptake inhibitors (SSRIs), which have become first-line therapy for
treatment of depression in cancer patients, are strongly protein-bound, and therefore
consideration must be given to their interaction with anticancer agents.16 Binding to
human serum albumin (HSA) may also affect the cytotoxicity and cellular accumulation
of platinum drugs as well as their structural integrity.17,

18, 19

In a cell-free assay, the

presence of equimolar concentrations of desipramine did not affect the binding of any of
the platinum drugs to human serum albumin (Figure 2.3). There are slight differences
between cisplatin and oxaliplatin at early time points but overall the antidepressant does
not affect binding of platinum drugs. Simultaneous binding of both types of drug to
albumin may well still occur – the binding sites may simply be different.

2.4.2b Cellular Platinum Accumulation
Platinum drug cellular accumulation in HCT-116 colon cancer cells was measured in
cells treated with platinum drug +/- desipramine (Figure 2.4 A,B,C). Desipramine
surprisingly enhanced the cellular accumulation of cisplatin more than 2 fold but in
contrast, neither oxaliplatin nor BBR3464 showed any difference in cellular
accumulation in the presence of the tricyclic (Figure 2.4). The somewhat higher
accumulation of oxaliplatin relative to cisplatin in human colon cancer cells at equimolar
concentrations was confirmed.20 Because of the more rapid accumulation of BBR3464
at early time points, accumulation for this agent was measured after 8 hours whereas a
16-hour time-point was used for the mononuclear drugs. The overall results did confirm
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the high cellular accumulation of the 4+ positively charged compound relative to the
neutral cisplatin and oxaliplatin at early time points in the absence of desipramine.15, 21

2.4.2c Cellular Platinum-DNA Binding
Another important parameter for platinum cytotoxicity is the extent of DNA binding. No
enhancement of platinum-DNA binding was found for either cisplatin or oxaliplatin in the
presence of desipramine (Figure 2.5). Some increase was found for BBR34364 but, by
itself, is unlikely to explain the enhancement of cytotoxicity by the anti-depressant.
Since cellular accumulation in the presence of desipramine is only enhanced in the case
of c-DDP (Fig. 2.4A), there appears to be no direct correlation between enhanced
accumulation and the levels of platinum-DNA adducts.
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Figure 2.3 Cisplatin, oxaliplatin and BBR3464 binding (with standard deviations) to Human Serum
Albumin (HSA) in the presence and absence of desipramine. The platinum drugs and desipramine are in
a 1:1 molar ratio. The drugs are in a 1:3 molar ratio to HSA. BBR3464 concentration is divided by 3 to
reflect the trinuclear nature of the drug.
34

Figure 2.4 The effect of desipramine on platinum-compound cellular accumulation. In A, B, C,
HCT116 cells were treated with equimolar concentrations (20µmol/L) c-DDP and Oxaliplatin for 16h
and BBR3464 for 8h, with the indicated concentrations of desipramine. Cellular platinum content was
measured by ICP-OES as described in method and materials. Each point represents the average (+/SEM) of three independent experiments. *, p<0.05 as compared to drug alone as determined by t test
35

Figure 2.5 Nanograms platinum per g DNA (with standard deviations) after a 36 hour exposure time to
the platinum drugs and 40 M desipramine. The concentration of the platinum drugs was chosen so that
-13
the moles platinum drug: cell ratio was 4x10 moles/cell
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2.4.3 Cellular and Signalling Effects of Desipramine on Platinum Drug
Combination.
2.4.3a Platinum Drug-Mediated p53 Expression
Pharmacological effects such as plasma protein binding, cellular accumulation and/or
the extent of cellular platinum-DNA binding cannot explain the desipramine-mediated
effects on platinum drug cytotoxicity. We have therefore investigated potential global
biological responses that could be augmented by desipramine.

Many apoptotic

signaling pathways converge at the transcription factor p53. p53 causes cell death in
part by inducing mitochondrial damage that activates the death effector caspase
enzymes.22 Since all platinum drugs have been argued to elicit apoptosis in certain cell
lines via a p53-dependent pathway23, 24, the level of p53 was measured by Western blot
analysis and quantified by densitometry (Figure 2.6). Interestingly, p53 levels in the
presence of desipramine alone were low – in agreement with the observation that, while
desipramine can induce apoptosis in a mitochondrial-dependent manner, HCT116 cells
are not especially sensitive to this agent.25 However, the combination of the platinum
drugs with desipramine showed an increase in p53 level.

This could be due to

increased p53 production or p53 stabilization. The increase in p53 in the presence of
desipramine resembled its augmentation of apoptosis with a measured increase for all
three agents.
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Figure 2.6 Effect of desipramine on p53 stabilization by cisplatin, and oxaliplatin and BBR3464. HCT116
cells were cultured with 10µmol/L cisplatin, 30µmol/L oxaliplatin or 50µmol/L BBR3464, in the absence
and presence 40µmol/L desipramine. The expression of p53 was detected by Western blotting. The same
membrane was stripped and re-probed for ERK to show protein loading. The assay was consistently
repeated three times. The fold change (by densitometry) was 1.2 in all cases for desipramine control and
6.1, 1.0 and 4.1 for cisplatin, oxaliplatin and BBR3464 respectively.
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2.4.3b Importance of the p53 Dependent Pathway in Induced Apoptosis
If the effects of desipramine on p53 expression are functionally significant, they should
be consistent with increased mitochondrial damage, activation of the downstream
death-inducing caspase enzymes and increased cleavage of the caspase substrate
PARP, all of which can be triggered by p53.22 The same drug concentrations employed
in the apoptosis assays of Figure 2.2 were used in these experiments. The effects of
desipramine on mitochondrial damage, caspase activation and total PARP levels
mirrored the effects on apoptosis and p53 expression (Figure 2.7). The integrity of the
mitochondrion was examined by measuring desipramine/platinum drug-mediated loss of
mitochondrial

membrane

potential

(Δψm),

which

leads

to

apoptosis.

Desipramine/platinum drug treatment significantly decreased Δψm, increasing the
percentage of cells showing reduced Δψm by approximately two orders of magnitiude
compared to those treated with cisplatin, oxaliplatin and BBR3464 alone (Figure 2.7A).
In a similar manner, caspase 3 activation was also increased in HCT116 carcinoma
cells treated with desipramine prior to cisplatin, oxaliplatin or BBR3464 addition (Figure
2.7B).

Finally, the expression of uncleaved PARP was decreased in HCT116

carcinoma cells treated under the same experimental conditions (Figure 2.7C). These
latter effects mimic the effect of desipramine on p53 stabilization, mitochondrial damage
and caspase activation (Fig. 2.6C).
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Figure 2.7 Effect of desipramine on downstream signaling pathways of p53 activated by c-DDP and oxaliplatin and
BBR3464. A. Effect on mitochondrial damage. HCT116 cells were cultured with 10µmol/L c-DDP, or 30µmol/L
oxaliplatin or 50µmol/L BBR3464 in the absence or presence of desipramine for 72h. Reduction in mitochondrial
membrane potential (m) was assessed by staining with [Di(OC6)3 as described in Materials and Methods. B.
Effect of desipramine on Platinum-drug-induced caspase activation. HCT116 cells were cultured as in (A). Cells
were stained for active caspase-3/7 as described in Materials and Methods. Data shown are the percent of the
population displaying active caspase-3/7. Each point represents the average (+/-SEM) of three independent
experiments. C. The effect of desipramine on uncleaved PARP expression. HCT116 were cultured as in (A). The
expression of uncleaved PARP was detected by western blotting. The same membrane was stripped and reprobed for ERK to show protein loading. Each experiment was consistently repeated three times. *, p<0.05 when
comparing cells treated with and without desipramine, by Student’s t-test. The fold change (by densitometry) in
Panel C was 0.92 for desipramine control and 0.13, 0.56 and 0.81 for cisplatin, oxaliplatin and BBR3464
respectively.
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2.5 Discussion
These results complement the published reports of anti-depressant mediated
interference of tamoxifen efficacy in breast cancer treatment.8,

9, 26

Tamoxifen is

standard adjuvant treatment for women with estrogen receptor-positive breast cancer
and is a preventative agent for women at high risk of developing breast cancer. Studies
have shown that three antidepressants– paroxetine, fluoxetine and bupropion – may
interfere with tamoxifen treatment by inhibiting the action of CYP2D6, the principal
metabolic enzyme that converts tamoxifen into the active form endoxifen.8, 9 Given the
seriousness of these findings it is imperative to examine the generality of these findings
across the anti-cancer armamentarium. The results presented here show that the
tricyclic antidepressant desipramine actually augments the cytotoxicity of platinum anticancer agents. To understand this interesting result, with potential clinical importance,
we have explored the comparative pharmacology and cellular biology of the platinum
drugs in the presence and absence of the antidepressant. Desipramine does not interact
with either cisplatin or [PtCl(dien)]Cl as monitored by 1HNMR experiments.

It is noteworthy that desipramine has differential effects on cellular accumulation of the
platinum agents yet enhances cytotoxicity of all platinum agents studied. Only the
cellular accumulation of c-DDP is affected by the presence of desipramine accumulation was increased 2.7 fold by desipramine, which may explain the more rapid
kinetics of apoptosis seen (48 hours for c-DDP vs. 72 hours for BBR3464 and
oxaliplatin) (Figure 2.4). It is plausible that increased accumulation of c-DDP is due to a
reduced recycling of a potential c-DDP importer or perhaps inhibition of an efflux
transporter. Desipramine inhibits the serotonin transporter and affects trafficking of
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transporters such as β-adrenoreceptors.12,

27-29

Desipramine had no consistent effect

upon platinum-DNA binding– only BBR3464 showed measurable increases in the
number of DNA adducts in the presence of the anti-depressant. This selective effect on
BBR3464 further demonstrates the distinct cellular pharmacology of this trinuclear
platinum compound but more importantly, emphasizes the broad effects of despiramine
on platinum chemotherapeutics.30,

31

The kinetics of DNA binding and indeed cellular

uptake of all three platinum agents are different and it is difficult therefore to examine
identical time points for both accumulation and DNA platination assays, nevertheless
the results are consistent in that, unlike the tamoxifen case, there is no direct correlation
of cellular pharmacology (plasma protein binding, cellular accumulation and/or cellular
platinum-DNA binding) with the enhancement of cytotoxicity by desipramine.

Within the realm of cell cycle arrest and apoptosis, perhaps no cell signaling pathway is
more relevant than p53 activation. All three platinum compounds stabilized p53
expression in HCT116 cells and desipramine further enhanced this effect. Desipramine
itself induces apoptotic cell death through both mitochondrial and non-mitochondrial
pathways in different colon carcinoma cells.25 Notably, p53 levels due to desipramine in
HCT116 cells is also not as significant as that caused by platinum agents and is
considered to cause apoptotic cell death primarily through disturbance of mitochondrial
function, although HCT116 sensitivity in general is less than that of HT29 cells.25 The
molecular mechanism of desipramine apoptosis however remains to be elucidated but
is unlikely to be a consequence of direct DNA modification.25, 32 Thus, complementary
signaling pathways may be activated in the presence of both drugs. In this scenario, the
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role of p53 may lie in enhancement of two pathways – one through direct DNA
modification and the second a multiple effect on signaling pathways through the
presence of p53, adding to the cellular stress.

The viability of HCT116 cells is not significantly altered in the presence of up to 50μM
desipramine25, suggesting that the results obtained here at the concentrations used may
have genuine pharmacological significance. The optimal concentration of desipramine
was well within the range of clinically relevant doses achieved in patients, although
there is some discrepancy in literature values - free desipramine concentration in the
serum has been reported at approximately 9.5 µM33, but toxicity has been noted at 3.8
μM.34

In conclusion, an unexpected result is the potentiation of cytotoxicity shown by
desipramine. The tricyclic organic compound, a safe and effective antidepressant
already in use for cancer treatment, greatly augments the cytotoxicity of platinum-based
chemotherapeutics. While the molecular mechanism of enhancement is clearly
complicated, and may indeed not be strictly the same for all platinum agents, the results
to date suggest that enhancement of weakly induced signaling pathways in the case of
desipramine may be exerted with greater efficiency, leading to the observation of drug
enhancement. These effects correlated to some extent with enhanced activation of the
p53-mitochondrial death pathway. The study suggests that desipramine may be a
means of enhancing chemo-responsiveness to platinum-based anticancer agents, and
warrants further investigation for its clinical utility. The results also stress the desirability
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of surveying similar cellular effects for tamoxifen, beyond the effect of antidepressants
on the drugs metabolic activation.
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CHAPTER 3: Platinum Anti-Cancer Agents
and Antidepressants: Cell Specificity, Drug
Specificity and the Role of Calmodulin

3.1 Abstract
This work examines the interactions of cisplatin, carboplatin and oxaliplatin with
desipramine in two human colon carcinoma cell lines (HCT116 wt and HT-29) as well as
two ovarian carcinoma cell lines (SKOV-3 and A2780). The effect of desipramine on
the cytotoxicity of the platinum drugs was both cell line specific and platinum drug
specific.

Specificity with regard to the antidepressant was also investigated.

The

tricyclic antidepressant imipramine and the selective serotonin re-uptake inhibitors
citalopram and fluoxetine were investigated with cisplatin, carboplatin and oxaliplatin in
HCT116 wt cells.

The two tricyclic antidepressants and fluoxetine had the largest

effects on the cytotoxicity of cisplatin, carboplatin and oxaliplatin. The role of p53 was
investigated by using HCT116 p53-/- cells. The data show that the observed effects on
platinum drug cytotoxicity by desipramine have both a p53-dependent and a p53independent portion. Interestingly, the tricyclic antidepressants and fluoxetine are
known calmodulin inhibitors. The role of calmodulin inhibition was investigated using
W7

(a

known

calmodulin

inhibitor,
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N-(6-Aminohexyl)-5-chloro-1-

naphthalenesulfonamide hydrochloride) along with the platinum drugs in HCT116 wt
and HCT116 p53-/- cells. Calmodulin inhibition effected the cytotoxicity of the platinum
chemotherapeutic agents in a similar manner to the antidepressants.

3.2 Introduction
Many cancer chemotherapeutic regimens include a combination of drugs.

The

platinum-based chemotherapeutic agents are frequently included in these combinations.
For instance, cisplatin in combination with other chemotherapeutic agents cures over
90% of testicular cancer cases1 while oxaliplatin in combination with 5-fluorouracil is
used to treat metastatic colon cancer.2

Many cancer patients receive adjuvant antidepressant therapy for depression as well as
to treat side effects of the cancer therapy, such as neuropathic pain. It is estimated that
25% of cancer patients will experience major depression at some point during their
illness.3 Given the frequency with which these drugs are concurrently prescribed, it is
very important to understand how antidepressants and antineoplastics interact – the
combination may be additive or it may be antagonistic.

The importance of this issue

has been highlighted by the recent discussion on the effects of selective serotonin
reuptake inhibitors on the efficacy of tamoxifen in breast cancer therapy.4, 5

We have previously shown that the tricyclic antidepressant desipramine (Figure 3.1)
augments the cytotoxicity of cisplatin, oxaliplatin and the pre-clinical platinum drug
BBR3464 in HCT116 wt cells. The data also demonstrated that only cisplatin had an
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increase in cellular accumulation while only BBR3464 had an increase in platinum-DNA
binding in the presence of desipramine.

Furthermore, desipramine did not affect

platinum drug binding to human serum albumin.6

This study builds on the work of Kabolizadeh et al. focusing on the clinically used
platinum drugs cisplatin, oxaliplatin and carboplatin.6

The cell specificity, drug

specificity and potential mechanisms of the previously observed augmentation of
cytotoxicity were examined. The structures of all the compounds investigated in this
study are shown in Figure 3.1.

Figure 3.1 Structures of the clinically used platinum drugs, the antidepressants and the calmodulin
inhibitor, W7.. A. Structures of the three clinically used platinum anti-cancer drugs. B. Structures of the
tricyclic antidepressants. C. Structures of the selective serotonin reuptake inhibitor antidepressants. D.
Structure of W7, a known calmodulin antagonist.
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3.3 Materials and Methods
3.3.1 Materials
HCT116 human colon carcinoma cells were a gift from Bert Vogelstein (Johns Hopkins
University, Baltimore MD). The HT-29, A2780 and SKOV3 cells were purchased from
ATCC (Manassas, Virgina, USA). McCoy’s 5a Medium Modified, RPMI, Fetal bovine
serum (FBS), L-glutamine, penicillin, streptomycin, HEPES buffer and sodium pyruvate
were all purchased from Biofluids (Rockville, MD). N-(6-Aminohexyl)-5-chloro-1naphthalenesulfonamide hydrochloride (W7) was purchased from Axxora (Farmingdale,
New York, USA).

3.3.2 Cell Systems and Culture Conditions
HCT116 wt, HCT116 p53-/-, HT-29, A2780 and SKOV-3 cells were used. The medium
used for the HT-29 cells was McCoy’s 5a Medium Modified with 10% fetal bovine
serum, 2 mmol/L L-glutamine, 100 U/mL penicillinin, 100 g/mL streptomycin, 10
mmol/L HEPES buffer and 1 mmol/L sodium pyruvate (McCoy’s, all from Biofluids,
Rockville, MD). The medium used for all other cell types was RPMI 1640 with 10% fetal
bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillinin, 100 g/mL streptomycin, 10
mmol/L HEPES buffer and 1 mmol/L sodium pyruvate (cRPMI, all from Biofluids,
Rockville, MD). The cells were cultured in 175 cm2 Cell Star tissue culture flasks from
Greiner Bio-One (Frickenhausen, Germany) in an incubator with 5% CO2 and humidified
air.
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3.3.3 Apoptosis Studies
Cells were cultured in 6 well plates with 7.0 x 10 4 cells per well. 3 mL medium was put
in each well.

Cells were treated for 24 hours, 48 hours or 72 hours with these

conditions: untreated, platinum drug by itself, antidepressant by itself, and platinum drug
plus antidepressant. The platinum drugs were added to the medium after a one-hour
treatment period with the antidepressant.

At the time points, all cells (adherent and

non-adherent) were collected. Samples were fixed in a solution containing 35% 1x PBS
(vol/vol), 12.48% fetal bovine serum (vol/vol), and 52.52% 70% ethanol (vol/vol). The
samples were then washed with phosphate buffered saline (PBS), and stained with a
solution containing 94% 1x PBS (vol/vol), 0.1 mg/mL RNase A, 0.0001 M EDTA, and
0.04 mg/mL propidium iodide (PI). The samples were stained for two hours. Samples
were then analyzed for subdiploid DNA content using a FACScan flow cytometer (BD
Biosciences, San Jose, CA). It is noteworthy that this protocol differs significantly from
the more common PI-based exclusion, which only differentiates live versus dead cells.
Through fixation and RNase A treatment, we were able to detect intact versus
fragmented DNA, revealing discrete stages of the cell cycle and the percentage of the
population undergoing apoptosis.

3.4 Results
3.4.1 Desipramine Enhances Carboplatin Cytotoxicity
The interaction of desipramine with carboplatin was investigated in HCT116 wt cells in
order to expand on the previous work that demonstrated that desipramine enhances the
cytotoxicity of cisplatin and oxaliplatin. Although carboplatin alone had low cytotoxicity
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in this cell line, the combination of carboplatin and desipramine was highly cytotoxic. At
72 hours, carboplatin alone caused 12% apoptosis while the combination of carboplatin
and desipramine caused 53% apoptosis (Figure 3.2). The combination was significantly
different from the percent of apoptosis caused by carboplatin alone at both the 48 and
72 hour time points. The p-values were 4.7 x 10-9 and 1.8 x 10-12 respectively.

Figure 3.2 Desipramine enhances the cytotoxicity of carboplatin in HCT116 wt cells. Carboplatin was 40
µM and desipramine was 40 µM. The error bars are ± the SEM. * denotes a p-value < 0.05.
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3.4.2 Survey of Cell Lines
3.4.2a HT-29 Cell Line
The interaction of desipramine with cisplatin, oxaliplatin and carboplatin was
investigated in HT-29 cells. The HT-29 cell line is another human colon carcinoma that
in the literature has been shown to respond differently to desipramine than HCT116 wt
cells.8 The results of the combination of the platinum based chemotherapeutics and
desipramine in the HT-29 cells were quite different from those seen in the HCT116 wt
cells. Desipramine decreased the cytotoxicity of cisplatin and increased the cytotoxicity
of oxaliplatin. At 72 hours, cisplatin alone caused 25% apoptosis while cisplatin plus
desipramine only caused 18% apoptosis.

The difference between the percent

apoptosis due to cisplatin and cisplatin plus desipramine has a p-value of 8.2 x 10-5
(Figure 3.3 A).

Oxaliplatin alone was significantly different from oxaliplatin plus

desipramine at both 24 and 72 hours but not at 48 hours. The combination of oxaliplatin
plus desipramine initially causes more apoptosis than oxaliplatin alone. By 48 hours,
the percent apoptosis caused by oxaliplatin alone has caught up to the percent
apoptosis caused by oxaliplatin plus desipramine. By 72 hours the percent apoptosis
caused by oxaliplatin alone has decreased slightly from what was observed at 48 hours
(from 10% to 9%) but this difference is not significant. The percent apoptosis from
oxaliplatin plus desipramine on the other hand has increased to 23% (Figure 3.3 B). In
the case of carboplatin, the addition of desipramine has little effect (Figure 3.3 C).
Although it is statistically different from carboplatin alone at 72 hours (p-value=0.01),
killing approximately 5% of a tumor is unlikely to have clinical significance.
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Figure 3.3 Effect of desipramine on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in HT-29 cells.
Cisplatin plus desipramine. B. Oxaliplatin plus desipramine. C. Carboplatin plus desipramine. D.
Concentrations of drugs used in this cell line. The error bars are ± the SEM. * denotes a p-value < 0.05.

3.4.2b A2780 Cell Line
The interaction of desipramine with cisplatin, oxaliplatin and carboplatin was
investigated in A2780 cells. The A2780 cell line is a human ovarian carcinoma cell line.
In this cell line desipramine augmented the cytotoxicity of cisplatin and carboplatin at
24, 48 and 72 hours. In the case of cisplatin, cisplatin alone caused 5% apoptosis at 24
hours while cisplatin plus desipramine caused 9% apoptosis. This has a p-value of
0.01. At 48 hours the difference was even more significant. Cisplatin alone caused
17% apoptosis while the combination with desipramine caused 50% apoptosis with a p-
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value of 2.4 x 10-8.

At 72 hours, cisplatin alone caused 42% apoptosis while the

combination of cisplatin plus desipramine caused 66% apoptosis with a p-value of 3.0 x
10-4 (Figure 3.4 A).

In the case of oxaliplatin, the combination of oxaliplatin plus desipramine is only
significantly different from oxaliplatin alone at 48 hours. At 48 hours, oxaliplatin alone
caused 49% apoptosis while the combination of oxaliplatin plus desipramine caused
67% apoptosis with a p-value of 8.0 x 10-4. At 72 hours, there is no statistical difference
between oxaliplatin and oxaliplatin plus desipramine. The percent apoptosis due to the
combination of oxaliplatin plus desipramine appears to decrease below that of
oxaliplatin alone. This is due to two samples which did not have as much apoptosis as
the rest of the samples. Although the samples were not statistical outliers by the Q test
and therefore could not be removed, if the data was analyzed without them the end
result was the same: the two conditions are not significantly different at 72 hours (Figure
3.4 B).

In the case of carboplatin, the combination of carboplatin plus desipramine is
significantly different from carboplatin alone at all three time points investigated. At 24
hours, carboplatin alone caused 4% apoptosis while carboplatin plus desipramine
caused 10% apoptosis with a p-value of 3.0 x 10-4. At 48 hours, carboplatin alone
caused 8% apoptosis while the combination with desipramine caused 16% apoptosis
with a p-value of 2.4 x 10-6. At 72 hours, carboplatin alone caused 25% apoptosis while
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carboplatin plus desipramine caused 40% apoptosis with a p-value of 1.9 x 10-5 (Figure
3.4 C).

Figure 3.4 Effect of desipramine on the the cytotoxicity of cisplatin, oxaliplatin and carboplatin in A2780
cells. A. Cisplatin plus desipramine. B. Oxaliplatin plus desipramine. C. Carboplatin plus desipramine. D.
Concentrations of drugs used in this cell line. The error bars are ± the SEM. * denotes a p-value < 0.05.

3.4.2c SKOV-3 Cell Line
The interaction of desipramine with cisplatin, oxaliplatin and carboplatin was
investigated in SKOV-3 cells.

The SKOV-3 cell line is a platinum-resistant human

ovarian carcinoma cell line. Desipramine was unable to reverse resistance in this cell
line.

Cisplatin plus desipramine, oxaliplatin plus desipramine and carboplatin plus
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desipramine were not significantly different from the platinum drugs by themselves at
any of the three time points investigated.

Figure 3.5 Desipramine has no effect on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in SKOV3 cells. A. Cisplatin plus desipramine. B. Oxaliplatin plus desipramine. C. Carboplatin plus desipramine.
D. Concentrations of drugs used in this cell line. The error bars are ± the SEM. * denotes a p-value
<0.05.

In summary, the effect of the individual drugs as well as the combination of drugs is cellline specific. Table 3.1 shows a summary of these data.
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Table 3.1 Summary of Cell Line Survey

Note: + Indicates that the percent apoptosis is greater than in the untreated control. ++ Indicates that the
combination is better than either drug alone. – Indicates that the percent apoptosis is not significantly
different from that observed in the untreated control. - - Indicates that the combination causes less
cytotoxicity than the platinum drug alone.

3.4.3 Platinum Drugs with Other Antidepressants
3.4.3a Imipramine in HCT116 wt Cells
In order to determine if the observed effect is specific to desipramine the interaction of
the platinum drugs with imipramine (Figure 3.1) was investigated.

Imipramine is

another member of the tricyclic antidepressant family. It differs from desipramine by the
addition of one methyl group. In combination with cisplatin, imipramine behaves very
much like desipramine.

Imipramine enhances the cytotoxicity of cisplatin and the

combination is significantly different from cisplatin alone at 24, 48 and 72 hours. At 24
hours, cisplatin alone caused 22% apoptosis while the combination of cisplatin and
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imipramine caused 34% apoptosis. This has a p-value of 0.009. At 48 hours, cisplatin
alone caused 53.8% apoptosis while the addition of imipramine caused 84% apoptosis
with a p-value of 4.6 x 10-8. At 72 hours, cisplatin alone caused 65% apoptosis but the
combination of cisplatin plus imipramine caused 90% apoptosis with a p-value of 8.1 x
10-9 (Figure 3.6 A).

Interestingly, imipramine inhibits the cytotoxicity of oxaliplatin and this is significant at all
three time points investigated. At 24 hours, oxaliplatin alone caused 7% apoptosis
while the combination of oxaliplatin plus imipramine caused only 3.5% apoptosis. This
has a p-value of 0.001. At 48 hours, oxaliplatin alone caused 35% apoptosis while the
combination with imipramine only caused 14% apoptosis. At 72 hours the difference is
even larger.

Oxaliplatin alone caused 60% apoptosis whereas oxaliplatin plus

imipramine only caused 34% apoptosis with a p-value of 0.0005 (Figure 3.6 B).

The combination of carboplatin and imipramine is not impressive (Figure 3.6 C).
Carboplatin plus imipramine is only significantly different from carboplatin alone at 48
hours. At 48 hours, carboplatin alone caused 6% apoptosis while the combination of
carboplatin plus imipramine caused 11% apoptosis (p=0.005). This is unlikely to be
clinically significant.
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Figure 3.6 Effect of imipramine on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in HCT116 wt
cells. A. Imipramine enhances the cytotoxicity cisplatin. B. Imipramine inhibits the cytotoxicity of
oxaliplatin. C. Imipramine has little effect on carboplatin cytotoxicity. D. Concentrations of drugs used in
this cell line. The error bars are ± the SEM. * denotes a p-value < 0.05.

3.4.3b Citalopram in HCT116 wt Cells
Citalopram is a member of the selective serotonin reuptake inhibitors (Figure 3.1). The
selective

serotonin

reuptake

inhibitors

are

the

most

commonly

prescribed

antidepressants. Citalopram augments the cytotoxicity of cisplatin at 24 and 48 hours
but not at 72 hours. At 24 hours, cisplatin alone caused 17% apoptosis while the
combination of cisplatin plus citalopram caused 24% apoptosis with a p-value of 0.01.
At 48 hours, cisplatin alone caused 44% apoptosis while the combination with
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citalopram caused 62% apoptosis with a p-value of 0.002. By 72 hours however, the
percent apoptosis caused by cisplatin alone was no longer significantly less than that
caused by the combination of cisplatin plus citalopram (Figure 3.7 A).

Oxaliplatin plus citalopram was not significantly different from oxaliplatin at 24 or 48
hours.

At 72 hours however, oxaliplatin plus citalopram caused significantly less

apoptosis than oxaliplatin alone. Oxaliplatin alone caused 55% apoptosis whereas the
combination of oxaliplatin plus citalopram caused only 40% apoptosis (Figure 3.7 B).
This has p-value of 0.02.

The combination of carboplatin with citalopram is unimpressive. Like oxaliplatin plus
citalopram, the combination of carboplatin plus citalopram is not significantly different
from carboplatin alone at 24 or 48 hours but at 72 hours, the combination causes less
apoptosis than carboplatin alone. At 72 hours, carboplatin alone caused 12% apoptosis
while carboplatin plus citalopram caused 7% apoptosis with a p-value of 2 x 10-4 (Figure
3.7 C). While this is a significant difference, killing 12% or 7% of a tumor is not likely to
be clinically useful.
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Figure 3.7 Citalopram has little effect on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in
HCT116 wt cells. A. Cisplatin plus citalopram. B. Oxaliplatin plus citalopram. C. Carboplatin plus
citalopram. D. Concentration of drugs used in this cell line.

3.4.3c Fluoxetine in HCT116 wt Cells
Another selective serotonin reuptake inhibitor is fluoxetine, which is better known as
Prozac (Figure 3.1). Fluoxetine augments the cytotoxicity of cisplatin in HCT116 wt
cells at all three time points investigated. At 24 hours, cisplatin alone caused 22%
apoptosis while the combination of cisplatin plus fluoxetine caused 46% apoptosis with
a p-value of 1.5 x 10-7. At 48 hours, cisplatin alone caused 54% apoptosis while the
combination with fluoxetine caused 85% apoptosis with a p-value of 5.3 x 10-8. At 72
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hours, cisplatin alone caused 65% apoptosis whereas cisplatin plus fluoxetine caused
87% apoptosis with a p-value of 2.2 x 10-6 (Figure 3.8 A). Fluoxetine has no effect on
the cytotoxicity of oxaliplatin in HCT116 wt cells (Figure 3.8 B).

Fluoxetine augments the cytotoxicity of carboplatin in HCT116 wt cells. At 24 hours,
carboplatin alone causes 6% apoptosis while the combination of carboplatin plus
fluoxetine causes 11% apoptosis with a p-value of 9.8 x 10-7. At 48 hours, carboplatin
alone caused 9% apoptosis whereas carboplatin plus fluoxetine caused 24% apoptosis
with a p-value of 2.3 x 10-6. At 72 hours, carboplatin alone caused 19% apoptosis while
the combination of carboplatin plus fluoxetine caused 60% apoptosis with a p-value of
5.1 x 10-10 (Figure 3.8 C).

3.4.4 Mechanistic Studies
3.4.4a The Role of p53
3.4.4a1 Platinum Drugs and Desipramine in HCT116 p53-/- Cells
The tumor suppressor gene p53 is often mutated in cancer cell lines, so it is important
to examine whether or not wild type p53 is required for the observed effect of
antidepressants on the cytotoxicity of platinum drugs. To investigate the role of p53, the
interaction of tricyclic antidepressants on the cytotoxicity of platinum drugs was studied
in the HCT116 p53-/- cell line. In the case of desipramine, augmentation of cytotoxicity
was observed with cisplatin, oxaliplatin and carboplatin (Figure 3.9). However, the
augmentation observed in the p53 knockout cell line was less than was observed in the
p53 wild type cell line. In the case of cisplatin, the combination of cisplatin plus
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Figure 3.8 Fluoxetine in HCT116 wt cells. A. Fluoxetine augments the cytotoxicity of cisplatin. B.
Fluoxetine has no effect on they cytotoxicity of oxaliplatin. C. Fluoxetine augments the cytotoxicity of
carboplatin. D. Concentrations of drugs used in these experiments. Error bars are ± the SEM. * denotes
a p-value < 0.05.
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desipramine augmented the cytotoxicity of cisplatin at 24, 48 and 72 hours but was only
significantly different at 48 and 72 hours.

At 48 hours, cisplatin alone caused 35%

apoptosis whereas cisplatin plus desipramine caused 58% apoptosis with a p-value of
5.1 x 10-5. At 72 hours, cisplatin alone caused 34% apoptosis while the combination of
cisplatin plus desipramine caused 70% apoptosis with a p-value of 9.8 x 10-8 (Figure 3.9
A).

Desipramine also augments the cytotoxicity of oxaliplatin in the HCT116 p53-/- cell line.
At 24 hours, oxaliplatin alone caused 9% apoptosis while oxaliplatin plus desipramine
caused 14% apoptosis. This difference has a p-value of 0.02. At 48 hours, oxaliplatin
alone caused 26% apoptosis whereas oxaliplatin plus desipramine caused 39%
apoptosis with a p-value of 0.006. At 72 hours, oxaliplatin alone only caused 21%
apoptosis while the combination with desipramine caused 50% apoptosis (Figure 3.9 B).
This difference has a p-value of 7.2 x 10-5.

Desipramine also enhances the cytotoxicity of carboplatin in the HCT116 p53-/- cell line.
At 24 hours, carboplatin alone caused 6% apoptosis while carboplatin plus desipramine
caused 14% apoptosis with a p-value of 0.0002.

Although the enhancement over

carboplatin alone is significant at 24 hours, carboplatin plus desipramine is not
significantly different from desipramine alone at 24 hours. At 48 hours, carboplatin
alone caused 10% apoptosis while the combination of carboplatin plus desipramine
caused 30% apoptosis with a p-value of 6.1 x 10-6. At 72 hours, carboplatin alone
caused 13% apoptosis whereas carboplatin plus desipramine caused 52% apoptosis
with a p-value of 1.4 x 10-11 (Figure 3.9 C).
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In the HCT116 p53-/- cells, less of an increase in cytotoxicity was observed due to the
desipramine plus platinum drug combination than was observed in the HCT116 wt cells.
For cisplatin plus desipramine, the difference between the percent apoptosis observed
in the HCT116 wt cells and the HCT116 p53-/- cells was significantly different at both 48
and 72 hours with p-values of 1.9 x 10-4 and 1.5 x 10-4 respectively. For oxaliplatin plus
desipramine, the difference between the percent apoptosis observed in the HCT116 wt
cells and the HCT116 p53-/- cells was also significantly different at both 48 hours and
72 hours with p-values of 4.2 x 10-3 and 1.2 x 10-3 respectively.

In the case of

carboplatin plus desipramine, the difference between the percent apoptosis observed in
the HCT116 wt cells and the HCT116 p53-/- cells is only significantly different at 48
hours with a p-value of 1.1 x 10-4.

3.4.4a2 Platinum Drugs and Imipramine in HCT116 p53-/- Cells
Given that in HCT116 wt cells, the platinum drugs with imipramine did not behave
exactly the same way as the platinum drugs with desipramine, it was important to
investigate whether or not the same effects were observed in the HCT116 p53-/- cells.
Imipramine augments the cytotoxicity of cisplatin. At 24 hours, cisplatin alone caused
6% apoptosis while the combination with imipramine caused 12% apoptosis.

This

difference had a p-value of 0.005. At 48 hours, cisplatin alone caused 15% apoptosis
while cisplatin plus imipramine caused 42% apoptosis with a p-value of 2.7 x 10-7. At 72
hours, cisplatin alone caused 29% apoptosis while the combination of cisplatin plus
imipramine caused 69% apoptosis. This difference had a p-value of 4.1 x 10-7 (Figure
3.10 A).
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Figure 3.9 Desipramine increases the cytotoxicity of cisplatin, oxaliplatin and carboplatin in HCT116 p53/- cells. A. Desipramine augments the cytotoxicity of cisplatin. B. Desipramine augments the cytotoxicity
of oxaliplatin. C. Desipramine augments the cytotoxicity of carboplatin. D. Concentrations of drugs used
in these experiments. Error bars are ± the SEM. * denotes a p-value < 0.05.
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Imipramine had very little effect on the cytotoxicity of oxaliplatin in HCT116 p53 -/- cells.
Although the combination of oxaliplatin plus imipramine did appear to trend towards
increased apoptosis, it was not significantly different from the percent apoptosis caused
by oxaliplatin alone at any of the three time points investigated (Figure 3.10 B).

Imipramine enhanced the cytotoxicity of carboplatin in HCT116 p53-/- cells at 48 hours
and 72 hours. At 48 hours, carboplatin caused 4 % apoptosis while carboplatin plus
imipramine caused 9% apoptosis. This difference had a p-value of 2.1 x 10-4. At 72
hours, carboplatin alone caused 12% apoptosis whereas the combination of carboplatin
plus desipramine caused 18% apoptosis. This difference had a p-value of 1.3 x 10-4
(Figure 3.10 C).

The comparison of the percent apoptosis due to the imipramine plus platinum drug
combination in the HCT116 wt cells and the HCT116 p53-/- cells is interesting. In the
case of cisplatin plus imipramine, the difference between the percent apoptosis
observed in the HCT116 wt cells and the HCT116 p53-/- cells was significantly different
at both 48 and 72 hours with p-values of 2.4 x 10-7 and 9.1 x 10-6 respectively. For
oxaliplatin plus imipramine, the difference between the percent apoptosis observed in
the HCT116 wt cells and the HCT116 p53-/- cells was not significantly different. In the
case of carboplatin plus imipramine, the percent apoptosis observed in the HCT116
p53-/- cells was significantly decreased from what was observed in the HCT116 wt cells
at 48 hours (p=0.01). However, there was no significant difference at 72 hours.
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Figure 3.10 Effect of imipramine on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in HCT116
p53-/- cells. A. Imipramine augments the cytotoxicity of cisplatin. B. Imipramine has no effect on the
cytotoxicity of oxaliplatin. C. Imipramine slightly augments carboplatin. D. Concentrations of drugs used
in these experiments. Error bars are ± the SEM. * denotes a p-value < 0.05.

3.4.4b Role of Calmodulin Inhibition
The tricyclic antidepressants9 and fluoxetine10 are known to be calmodulin inhibitors.
Given this, it was important to investigate the role of calmodulin inhibition in the
observed effects on cytotoxicity. To do this, the percent apoptosis due to the platinum
drugs was measured in the presence and absence of N-(6-aminohexyl)-5-chloro-1naphthalenesulfonamide hydrochloride (W7), a known calmodulin inhibitor.11 This was
done using both HCT116 wt cells and HCT116 p53-/- cells.
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3.4.4b1 Role of Calmodulin Inhibition in HCT116 wt Cells
In the HCT116 wt cells, the combination of the platinum drugs with W7 mirrors the
results observed with imipramine. W7 augments the cytotoxicity of cisplatin at 24, 48
and 72 hours. At 24 hours, cisplatin alone caused 14% apoptosis while cisplatin plus
W7 caused 25% apoptosis with a p-value of 0.01. At 48 hours, cisplatin caused 36%
apoptosis while the combination with W7 caused 70% apoptosis. This difference had a
p-value of 4.67 x 10-6. At 72 hours, the percent apoptosis caused by cisplatin remained
at 36% while the percent apoptosis due to cisplatin plus W7 increased to 77% (Figure
3.11 A). This difference had a p-value of 1.8 x 10-6.

W7 inhibited the cytotoxicity of oxaliplatin at both 48 and 72 hours.

At 48 hours,

oxaliplatin alone caused 51% apoptosis while oxaliplatin plus W7 caused 34%
apoptosis. This difference had a p-value of 0.001. At 72 hours, oxaliplatin caused 65%
apoptosis whereas the combination of oxaliplatin plus W7 only caused 47% apoptosis
with a p-value of 0.01 (Figure 3.11 B). W7 has very little effect on the cytotoxicity of
carboplatin in HCT116wt cells. The percent apoptosis due to carboplatin plus W7 was
not significantly different from the percent apoptosis due to carboplatin alone at any of
the three time points investigated (3.11 C).
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Figure 3.11 Calmodulin inhibition by W7 augments the cytotoxicity of cisplatin and inhibits the cytotoxicity
of oxaliplatin in HCT116 wt cells. A. W7 augments the cytotoxicity of cisplatin. B. W7 inhibits the
cytotoxicity of oxaliplatin. C. W7 has no effect on they cytotoxicity of carboplatin. D. Concentrations of
the drugs used in these experiments. Error bars are ± the SEM. * denotes a p-value < 0.05.

3.4.4b2 Role of Calmodulin Inhibition in HCT116 p53-/- Cells
In the HCT116 p53-/- cells, the results are a little different than they are in the HCT116
wt cells. W7 still augments the cytotoxicity of cisplatin, but not as much as it does in the
HCT116 wt cells. At 24 hours, cisplatin alone caused 6% apoptosis while cisplatin plus
W7 caused 9% apoptosis with a p-value of 0.002. At 48 hours, cisplatin caused 15%
apoptosis while the combination of cisplatin plus W7 caused 36% apoptosis.

This

difference had a p-value of 9.3 x 10-4. At 72 hours, cisplatin caused 29% apoptosis
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whereas cisplatin plus W7 caused 60% apoptosis with a p-value of 3.1 x 10

-9

(Figure

3.12 A).

The percent apoptosis due to the combination of oxaliplatin plus W7 was not
significantly different from the percent apoptosis due to oxaliplatin alone at any of the
three time points investigated (3.12 B). It is interesting to note that W7 inhibits the
cytotoxicity of oxaliplatin in HCT116 wt cells but not in HCT116 p53-/- cells. The reason
for this is unclear.

W7 enhanced the cytotoxicity of carboplatin at 48 hours. At 48 hours, carboplatin alone
caused 4% apoptosis while the combination of carboplatin plus W7 caused 7%
apoptosis (3.12 C, p=3.1 x 10-5). Although statistically significant, this is unlikely to be
clinically significant.
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Figure 3.12 Effect of calmodulin inhibition on the cytotoxicity of cisplatin, oxaliplatin and carboplatin in
HCT116 p53-/- cells. A. W7 augments the cytotoxicity of cisplatin. B. W7 has no effect on the
cytotoxicity of oxaliplatin. C. W7 slightly augments the cytotoxicity of carboplatin at 48 hours. D.
Concentrations of drugs used in these experiments. Error bars are ± the SEM. * denotes a p-value <
0.05.

3.5 Discussion
Previous work has shown that desipramine augments the cytotoxicity of cisplatin and
oxaliplatin in HCT116 wt cells.6

This work has built upon that by showing that

desipramine also augments the cytotoxicity of carboplatin in HCT116 wt cells.

It has also been shown that the observed effects are cell line specific as well as drug
specific with regard to the platinum drugs. Two colon carcinoma cell lines, HCT116 wt
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and HT-29, as well as two ovarian carcinoma cell lines, SKOV-3 and A2780, were
investigated. In the HCT116 wt cells, desipramine augmented the cytotoxicity of all
three platinum drugs investigated.

In the HT-29 cells however, desipramine only

augmented cisplatin at 72 hours and oxaliplatin at 24 and 48 hours. The SKOV-3 cell
line is a platinum resistant cell line.

The addition of desipramine was unable to

overcome this resistance. In the A2780 cell line however, desipramine augmented both
cisplatin and carboplatin. It also augmented oxaliplatin cytotoxicity at 48 hours.

This work also demonstrated that the observed effects are also drug specific with regard
to the antidepressants.

Imipramine, another tricyclic antidepressant, differs from

desipramine by one methyl group but behaves quite differently with the three platinum
drugs investigated.

In HCT116 wt cells, imipramine enhances the cytotoxicity of

cisplatin but inhibits the cytotoxicity of oxaliplatin. Imipramine has little effect on the
cytotoxicity of carboplatin. It is important to keep in mind however that desipramine is
an active metabolite of imipramine.12 Therefore, in a clinical setting this data may not
replicate exactly or may appear to be more of a mix between the results observed with
desipramine and the results observed with imipramine.

The selective serotonin reuptake inhibitors, citalopram and fluoxetine were also
investigated due to the frequency with which they are prescribed.
enhances the cytotoxicity of cisplatin at the early time points.

Citalopram only
Although there is

enhancement of cytotoxicity, it is less than was observed with desipramine and
imipramine.

By 72 hours, cisplatin and cisplatin plus citalopram cause the same
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amount of apoptosis. Although citalopram has no effect on the cytotoxicity of oxaliplatin
at the early time points, it does inhibit the cytotoxicity of oxaliplatin at 72 hours.
Citalopram has little effect on the cytotoxicity of carboplatin. Fluoxetine on the other
hand, strongly enhances the cytotoxicity of cisplatin. It also augments the cytotoxicity of
carboplatin in HCT116 wt cells but it does not augment the cytotoxicity to the same
extent that desipramine does. Fluoxetine has no effect on the cytotoxicity of oxaliplatin.

To investigate the mechanisms behind these observations, the role of p53 was
examined.

In the HCT116 p53-/- cells, desipramine augmented the cytotoxicity of

cisplatin, oxaliplatin and carboplatin.

Although enhancement of cytotoxicity was

observed in both the p53 wild type cells and the p53 knock out cells, the enhancement
observed in the p53 knock out cells was less than what was seen in the wild type cells.
This suggests that the observed effect has two mechanisms at work: one involving p53
and one that is p53 independent.

Similar results are seen with imipramine when

combined with cisplatin in the HCT116 p53-/- cells.

In the case of oxaliplatin plus

imipramine in the HCT116 p53-/- cells, the percent of apoptosis observed was not
significantly different from the percent apoptosis due to oxaliplatin alone. In the case of
carboplatin plus imipramine, the percent apoptosis observed in the HCT116 p53-/- cells
was significantly decreased from what was observed in the HCT116 wt cells at 48
hours. By 72 hours, this difference is no longer observed. Taken together, these data
suggest that there are at least two mechanisms at work. One of these mechanisms
appears to p53 independent while the other appears to be p53 dependent.
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The

platinum drugs themselves may use these mechanisms to different extents which could
explain the oxaliplatin data.

Since the tricyclic antidepressants9 and fluoxetine10 are known to be calmodulin
inhibitors, it was important to investigate the role of calmodulin inhibition. In both the
HCT116 wt and HCT116 p53-/- cells, the results of calmodulin inhibition were similar to
the results due to imipramine.

Calmodulin inhibition augmented the cytotoxicity of

cisplatin in both cell lines, however the enhancement was less in the HCT116 p53-/cells. Calmodulin inhibition by W7 also inhibited oxaliplatin cytotoxicity in HCT116 wt
cells while having little effect in HCT116 p53-/- cells. W7 had no effect on carboplatin
cytotoxicity in HCT116 wt cells but did enhance carboplatin cytotoxicity at 48 hours in
the HCT116 p53-/- cells.

In conclusion, it has been shown that these drug effects on cytotoxicity of platinum
drugs are both drug and cell line specific. The data suggest that there are multiple
mechanisms involved in the observed effects.

It is clear that there are both p53

dependent and independent components to this mechanism.

The platinum drugs

themselves may utilize these different mechanisms to different extents. This work has
also shown that calmodulin inhibition plays a role in the mechanism.

To further determine the mechanism(s), Western blots for pro-apoptotic proteins such
as p21 and Bax could be performed. This would allow comparison of protein levels in
cells that have been treated with the platinum drugs alone, the antidepressants alone,
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or the combination of platinum drug plus antidepressant. These experiments may show
differences in protein activation/induction between the different combinations.

This

would help elucidate whether one pathway or set of pathways is involved in the effects
observed with all platinum drug/antidepressant combinations or whether different drug
combinations utilize different pathways that happen to result in similar effects on
cytotoxicity. Since the data suggests that there is a p53 independent mechanism as
well, the role of the death receptors should be investigated. Once the mechanism is
fully elucidated, members of the responsible pathway(s) could be used as new drug
targets.

It is also possible that if more cell lines were investigated, patterns with regard to
cytogenetic abnormalities or over-expression of a particular protein may be observed.
Observations of this type would suggest which cell features are necessary to observe
the augmentation of platinum drug cytotoxicity due to the presence of an
antidepressant.

This would be particularly useful in moving cancer chemotherapy

towards personalized medicine.
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CHAPTER 4: Heparanase Inhibition by Positively
Charged Platinum-Based Chemotherapeutics

4.1 Abstract
This work examines the interaction between the positively charged platinum-based
chemotherapeutics (BBR3464, AH44 and AH78) and the model substrate fondaparinux.
The positively charged platinum based chemotherapeutics blocked fondaparinux
cleavage by both heparinase and heparanase. The enzyme inhibition with respect to
AH44 and AH78 was charge dependent.

Surprisingly, BBR3464 inhibited enzyme

activity more than AH44 despite being less positively charged. Time course studies
showed

that

the

interaction

between

the

positively

charged

platinum-based

chemotherapeutics and the fondaparinux is instantaneous. It further suggested that
BBR3464 may have an initial electrostatic binding followed by covalent binding whereas
AH44 and AH78 can only bind electrostatically. The results suggest that the positively
charged platinum-based chemotherapeutics may be able to reduce the increased
angiogenesis and metastasis observed with heparanase over-expression in cancer.
4.2 Introduction
Platinum-based chemotherapeutics are often used in cancer therapy but acquired
resistance is a frequent problem. This acquired resistance can lead to patient relapse.
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Decreased drug accumulation is a common cause of clinical chemoresistance. 1 For this
reason, we have focused on the uptake mechanisms of positively charged platinumbased chemotherapeutics and the possible implications of these uptake mechanisms.

Poly(arginine) sequences are commonly used as a recognition motif in protein-nucleic
acid recognition. This interaction is mediated by hydrogen bonds between the charged
guanidine groups of the arginine and the phosphate backbone oxygens of the
oligonucleotide to form what is known as an arginine fork. 2 A similar binding interaction
has been characterized in between duplex DNA and the non-covalent polynuclear
platinum complexes (AH78 and AH44). In this case, there is hydrogen bonding to the
phosphate oxygen from two cis-oriented amine (RNH2) and ammine (NH3) groups to
form what is known as a phosphate clamp.3, 4 The arginine fork and phosphate clamp
are shown in Figure 4.1.

It is also known that proteins containing poly(arginine) sequences are efficiently taken
up by cells due to interactions with proteoglycans on the cell surface. 5 The similarity
between the arginine fork and the phosphate clamp raises the question: Do the
positively charged platinum-based chemotherapeutics interact with proteoglycans in a
similar way to the arginine? Silva et al. have discovered that the answer to this question
is: Yes.6 The positively charged platinum-based chemotherapeutics were shown to bind
to heparan sulfate proteoglycans on the cell surface. Furthermore, the heparan sulfate
proteoglycans were necessary for uptake of the positively charged platinum-based
chemotherapeutics. This is a newly discovered mode of uptake for platinum drugs. 6
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Figure 4.1 Illustration of the arginine fork and the phosphate clamp. From: Silva H, Frézard F,
Peterson EJ, Kabolizadeh P, Ryan JJ, Farrell NP (2012) Mol Pharm 9:1795-1802
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4.2.1 Glycosaminoglycans
Glycosaminoglycans are complex carbohydrate molecules that are present on the cell
surface as well as in the extracellular matrix and the basement membrane.7, 8 They are
linear polysaccharides made up of repeating disaccharide units, which are composed of
uronic acid (D-glucoronic acid or L-iduronic acid) and a hexosamine (D-galactosamine
or D-glucosamine). Glycosaminoglycans are often highly sulfated which makes them
negatively charged.8
sulfate

and

Hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratin

heparan

sulfate

are

examples

of

glycosaminoglycans.8

Glycosaminoglycans may be in solution or may be bound to a protein core yielding a
proteoglycan.8

Proteoglycans have enormous heterogeneity. This is due to different protein cores,
variations in the length of the glycosaminoglycan chains as well as in the number of
chains attached, and the different types of glycosaminoglycan chains.8 Further variation
is inherent due to different possible sulfation patterns on the repeating disaccharide
units of the glycosaminoglycan chains.9

Glycosaminoglycans are able to interact with many proteins and are involved in both
normal

physiological

processes

as

well

as

pathological

processes.8

Glycosaminoglycans and their proteoglycan counterparts have been shown to have a
role in cell signaling and development8, 10, angiogenesis11, anti-coagulation12, 13, axonal
pathfinding14, neurotransmisson11, tumor progression9, 10 and metastasis.9, 15 Heparan
sulfate proteoglycans play a role in the pathology of amyloid diseases such as
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Alzheimer’s disease.8,

16, 17

They also facilitate host cell invasion by pathogens

including meningococcus16, Bordetella pertussis, Mycobacterium tuberculosis, herpes
simplex virus8, Plasmodium, Dengue fever and HIV.8, 16

4.2.2 Heparan Sulfate Proteoglycans
Heparan sulfate proteoglycans are present on both the cell surface as well as in the
extracellular matrix and the basement membrane.15

Soluble heparan sulfate

proteoglycans are bound in the extracellular matrix and the serum. Heparan sulfate
proteoglycans are very important for many normal physiological functions. They are
involved in cell-cell adhesion as well as cell-extracellular matrix adhesion. They can
also act as co-receptors for growth factors and they can facilitate the storage of heparinbinding proteins for future mobilization.7, 15

Heparan sulfate proteoglycans are found in very high concentrations (micromolar range)
and can have half-lives of hours to days. For this reason, the signaling events mediated
by heparan sulfate proteoglycans are often long lasting.

These events may be

paracrine or autocrine in nature.11

Heparan sulfate proteoglycans can act as receptors and modulate protein signaling in
several ways.

One mechanism involves the heparan sulfate proteoglycan binding

several ligand molecules resulting in their oligomerization. The ligands on the heparan
sulfate proteoglycan-ligand complex can then monovalently bind to several receptors.
The receptors are able to dimerize and signaling results.18 An important point of this
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mechanism is that the heparan sulfate proteoglycans also bind to the receptors as well
as the ligands. This interaction stabilizes the ternary complex.19 This mechanism is
used by fibroblast growth factors.18 A second very similar mechanism involves the
heparan sulfate proteoglycans acting as a template for ligand dimerization.

The

dimerized ligand is then able to bind to two receptors leading to receptor dimerization
and signaling. This is thought to be the mechanism used by many growth factors.9 A
third mechanism involves the heparan sulfate proteoglycans inducing a conformational
change in the ligand upon binding which causes the ligand to go from an inactive form
to an active form. An example of a ligand that utilizes this mechanism is antithrombin.
When antithrombin binds to heparan sulfate glycosaminoglycans, the antithrombin
becomes an active inhibitor of thrombin and factor Xa. Because thrombin and factor Xa
are involved in the coagulation cascade, this example also demonstrates how heparan
sulfate glycosaminoglycans are involved in hemostasis.9 As mentioned earlier, heparan
sulfate proteoglycans are involved in both cell-cell adhesion and cell-extracellular matrix
adhesion. In cell-extracellular matrix adhesion, heparan sulfate proteoglycans bind to
fibronectin in the extracellular matrix. This along with integrin binding to fibronectin
causes the formation of focal adhesions.20, 21

Heparan sulfate proteoglycans are also important in cellular uptake of polycationic
macromolecules. HIV-TAT is an example of a protein that uses this entry mechanism.
HIV-TAT has six arginine residues that are positively charged under physiological
conditions.5 The arginines bind to heparan sulfate proteoglycans on the cell surface
resulting in internalization of the HIV-TAT peptide.22

87

Heparan sulfate proteoglycans have also been shown to mediate cell entry for positively
charged tri-platinum compounds.6

Due to the fact that nonaarginine is the most

efficiently transported ‘protein transduction domain’5, Silva et al. used a TAMRA (5-(and
6-) carboxytetramethylrhodamine) tagged nonaarginine to investigate how different
platinum drugs competed with the nonaarginine for cellular internalization in wild type
CHO cells. The neutral platinum compounds cisplatin and oxaliplatin did not inhibit the
internalization of the nonaarginine.

However, the positively charged tri-platinum

compounds BBR3464, AH44 and Triplatin NC (aka AH78) prevented internalization of
the nonaarginine in a charge-dependent manner. BBR3464 with a charge of +4 and
AH44 with a charge of +6 decreased the nonaarginine internalization while Triplatin NC
with a charge of +8 completely inhibited internalization of the nonaarginine. This was
also examined in two cancer cell lines: the human colon carcinoma HCT116 and the
osteosarcoma SAOS-2. Interestingly, the positively charged tri-platinum drugs showed
increased inhibition of nonaarginine internalization in the tumor cell lines compared to
the normal CHO cells.

This suggests that these drugs may have some tumor

selectivity. To confirm that heparan sulfate proteoglycans were responsible for these
observations, Silva et al. investigated the cellular accumulation of the platinum drugs in
CHO cells, heparan-sulfate deficient CHO cells and heparan- and chondroitin-sulfate
deficient CHO cells. The cellular accumulation of BBR3464, AH44 and Triplatin NC was
reduced in the CHO mutants confirming the role of proteoglycans.6
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4.2.3 Heparanase and Heparinase
Heparanase is a mammalian endoglycosidase, which cleaves heparan sulfate by a
hydrolysis mechanism.23

It is important in the degradation and remodeling of the

extracellular matrix.24 Heparanase is also secreted by normal invasive cells such as
cytotrophoblasts in the placenta as well as by malignant cells.7

Heparinase, the

bacterial form of the mammalian enzyme heparanase, cleaves heparan sulfate by an
elimination mechanism.

There are three heparinases.

Heparinase I cleaves the

glycosidic linkage to the non-reducing end of iduronic acid. Heparinase II can cleave at
the same point as heparinase I as well as cleaving the heparan sulfate next to the
glucuronic acid, the site of cleavage by heparinase III.23 Heparinase I is frequently used
in the literature as an in vitro model for heparanase. The cleavage of fondaparinux (a
pentasaccharide used as a model for heparan sulfate), by the mammalian heparanase
and the bacterial heparinase I is shown in Figure 4.2.

4.2.4 Glycosaminoglycans, Proteoglycans and Cancer
Cancer, the uncontrolled division of abnormal cells in the body, arises when cells incur
mutations in proto-oncogenes and tumor suppressors that would normally regulate the
cell cycle and control DNA repair.7 Many tumors have alterations in their expression of
glycosaminoglycans.

They may express epitopes that are typically expressed in

embryonic tissues and only a few adult cell types.

These are known as oncofetal

antigens. In other cases, tumors may under express certain glycosaminoglycans or
they may have truncated or altered versions of glycosaminoglycans when compared to
normal tissues.7
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Figure 4.2 Comparison of fondaparinux cleavage by heparanse and heparinase I. Cleavage of fondaparinux
by heparanase (A). Cleavage of fondaparinux by heparinase I (B).

90

Heparan sulfate proteoglycans are quite important in cancer. For example, pancreatic
carcinoma cells over express glypican-1, a glycosylphosphatidylinositol anchored
heparan sulfate proteoglycan. It is also over expressed by the fibroblasts surrounding
the tumor. Glypican-1 binds fibroblast growth factor 2 and heparin-binding EGF-like
growth factor, two growth factors that are also commonly over expressed by pancreatic
carcinomas.

Glypican-1 is necessary for cell proliferation to result from these two

growth factors.25

Heparan sulfate proteoglycans may also have a role in epithelial differentiation and in
some cases tumor suppression.7 For example, if there are mutations or deletions in the
gene

for

glypican-3,

a

glycosylphosphatidylinositol

anchored

heparan

sulfate

proteoglycan, a congenital overgrowth syndrome called Simpson-Golabi-Behmel
syndrome results.7 Among many other symptoms, these patients have an increased
risk of developing embryonal cancers. They also have an increased risk of developing
neuroblastoma and hepatocellular carcinoma.26

An important glycoprotein in cell-cell adhesion is E-cadherin. E-cadherin mediates cellcell adhesion through homotypic interactions.7 The cytoplasmic domain of E-cadherin is
attached to actin filaments of the cytoskeleton by catenins.27

In cancer,

hypermethylation of the promoter region of the E-cadherin gene is frequently observed.
This leads to silencing of the E-cadherin gene and reduced cell-cell adhesion. The
reduction in cell-cell adhesion makes it possible for cancer cells to escape the primary
cancer site. Loss of function mutations in the genes for E-cadherin and the catenins
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have also been reported in cancer.

Furthermore, a glycoprotein known as dysadherin

is frequently expressed in colorectal carcinomas.

Dysadherin down regulates E-

cadherin. All of these abnormalities decrease cell-cell adhesion allowing cancer cells to
become more invasive.27

Integrins are very important proteoglycans involved in cell-extracellular matrix adhesion.
They mediate cellular attachment to fibronectin and laminin in the extracellular matrix.7
The integrin α5β1 is a primary fibronectin receptor.28 In many types of malignant cells,
the enzyme N-acetylglucosaminyltransferase V (GnTV) is over expressed.7

N-

acetylglucosaminyltransferase V is an enzyme that transfers N-acetylglucsoamine to
glycans and increases β1,6-branches on the growing glycans. It has been shown that
GnTV increases the β1,6-branches on the β1 subunit of the α5β1 integrin. The increase
in β1,6-branching on the β1 subunit reduces the ability of α1β5 integrins to cluster in the
cell membrane. This results in the inhibition of attachment and spreading of cells on
fibronectin as well as the stimulation of cell migration and invasion.28

Glycosaminoglycans and their proteoglycan counterparts also play an important role in
tumor metastasis.7 Metastasis is tumor cell dissemination to areas that are distant from
the primary tumor. This dissemination can occur by two mechanisms: 1) Cancer cells
can invade the blood or the lymph vessels of the tumor. 2) Cancer cells can also directly
invade into body cavities or spaces around the organs.29 When cancer cells invade the
blood

stream,

selectins

(intercellular

adhesion

molecules

that

bind

to

glycosaminoglycans) on platelets and leukocytes form complexes with the tumor cells.
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This complex formation helps the tumor cells lodge in blood vessels and also helps the
tumor cells avoid immune effector cells in the circulation.30, 31 Futhermore, tumors can
shed individual cells or clumps of cells containing cancer cells as well as stromal cells
such as fibroblasts. Interestingly, it has been found that the heterotypic cell clumps
contained a higher percentage of viable cancer cells than the individual or doublet
cancer cells in the circulation.

The clumps of cells are more efficient at forming

metastatic sites and the stromal cells survive the circulation and are involved in
metastatic growth at the secondary site.32

Circulating cancer cells have also been

shown to self-seed established tumor sites. These seeder cells are able to accelerate
tumor growth. One of the chemoattractants responsible for the self-seeding was tumor
derived IL-8.33 IL-8 binds to heparan sulfate7, 34 stabilizing it in an active conformation34
so the observed self-seeding is also mediated by glycosaminoglycans.

4.2.5 Heparanase and Cancer
Many tumors overexpress heparanase.35 As mentioned earlier, heparan sulfate
proteoglycans in the extracellular matrix can bind large quantities of heparin binding
growth factors such as fibroblast growth factor 2 and vascular endothelial growth factor.
This protects the growth factors from proteolysis or denaturation. When tumor cells
secrete heparanase, the heparanase cleaves the heparan sulfate proteoglycans and
releases the bound growth factors. The released growth factors can then be utilized by
the invading tumor cells.7 Heparanase also opens up the extracellular matrix and the
basement membrane making it possible for cancer cells to migrate.29 In patients, this
overexpression of heparanase has been correlated with increased tumor vasculature,

93

increased metastasis to lymph nodes as well as to more distant sites, and decreased
post-operative survival.24

Given that the over-expression of heparanase leads to a pro-angiogenic and prometastatic state24, the inhibition of heparanase activity is a potential target for anticancer therapies. The work of Silva et al. raises the question: Since the positively
charged platinum based chemotherapeutics bind to heparan sulfate, can they also
inhibit heparanase activity by inhibiting the enzyme-substrate interaction?

The work presented in this chapter examines the relationship between heparanse and
the positively charged platinum-based chemotherapeutics.

The data show that the

positively charged platinum-based chemotherapeutics bind to the model substrate
fondaparinux (Figure 4.3) and inhibit the enzymatic activity of both heparinase (the
bacterial form of the enzyme) and heparanse (the human form of the enzyme).
Inhibition of heparanase activity represents a new mechanism of action for platinum
antitumor compounds. We hypothesize that the positively charged platinum-based
chemotherapeutics may offer a way to treat resistant cancer cells as well as reducing
angiogenesis and metastasis.
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Figure 4.3 Structures of fondaparinux, cisplatin and the positively charged platinum complexes
BBR3464, AH44 and AH78.
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4.3 Materials and Methods
4.3.1 Materials
Fondaparinux was manufactured by Gland Pharma Limited (India) for Dr. Reddy’s
Laboratories Limited (Bachepalli, India). The heparinase I, cytodex 3 microcarriers, cold
collagen type I, fibrinogen and aprotinin were purchased from Sigma Aldrich (St. Louis,
Mo, USA). Thrombin was purchased from ZymoGenetics (Seattle, Washington, USA).
2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium
salt (WST-1) was purchased from Dojindo Laboratories (Kamimashiki-gun, Japan). All
platinum drugs were synthesized in the lab according to published methods.36, 37 The
R9-Tat protein was purchased from AnaSpec (Fremont, California, USA).
4.3.2 Heparinase Dose Response and Inhibition in Relation to Charge
In order to determine what concentration of the platinum drugs are necessary to inhibit
heparinase activity and how the charge on the platinum drugs effects heparinase
activity, an in vitro colorometric assay was used.38

To do this, a standard curve was

constructed using fondaparinux in a 40 mM sodium acetate buffer (pH 5.0) in each 96well plate. The standard curve was over the range 0 uM – 200 uM fondaparinux. For
the samples, 40 µM fondaparinux was placed in the wells of a 96-well plate. The
appropriate concentration of each platinum drug or R9-Tat protein was then added to
the wells. The plate was then incubated at 37 °C for 23 hours. After the incubation
period, heparinase I (Sigma Aldrich, from Flavibacterium heparinum) was added to each
well so that the final concentration was 0.28 µM. The plate was then incubated at 37 °C
for 3 hours.

A 1.69 mM solution of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-

disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1) was then produced in a 0.1 M
96

NaOH solution. A 100 µL aliquot of this WST-1 solution was added to each well to stop
the assay.

The plates were covered with Parafilm and developed at 60 °C for 60

minutes. The absorbance was measured at 584 nm using a µQuant plate reader (BioTek Instruments, Inc).

4.3.3 Determination of the Length of Fondaparinux-Platinum Drug Pre-Incubation
Necessary for Heparinase Inhibition
In order to determine how long it takes for the platinum drugs to inhibit heparinase
activity, the in vitro colorimetric assay was once again used. In each 96-well plate, a
standard curve was constructed using fondaparinux in a 40 mM sodium acetate buffer
(pH 5.0). The standard curve was over the range 0 µM – 200 µM fondaparinux. For the
samples, 40 µM fondaparinux was placed in the wells of a 96-well plate.

The

appropriate concentration of each platinum drug was then added to the wells. At 0,
0.17, 3 and 6 hours heparinase I (Sigma Aldrich, from Flavibacterium heparinum) was
added to each well so that the final concentration was 0.28 µM. The plate was then
incubated at 37 °C for 3 hours. A 1.69 mM solution of WST-1 was then made in a 0.1 M
NaOH solution. A 100 µL aliquot of this WST-1 solution was added to each well to stop
the assay.

The plates were covered with Parafilm and developed at 60 °C for 60

minutes. The absorbance was measured at 584 nm using a µQuant plate reader (BioTek Instruments, Inc).
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4.3.4 HCT116 wt and p53-/- Growth Conditions
HCT116 wt and HCT116 p53-/- cells were grown in RPMI 1640 with 10% fetal bovine
serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 1
mmol/L sodium pyruvate (cRPMI, all from Biofluids, Rockville, MD) in humidified air with
5% CO2.

4.3.5 Heparanase with Cells
15 x 103 HCT116 wt or HCT116 p53-/- cells/well were plated in a 96-well plate. Cells
were allowed to grow in cRPMI for 72 hours until nearly confluent before treating. After
cells had been allowed to adhere, the medium was removed and the cells were washed
with PBS. The cells were then treated. Conditions were either Untreated (PBS), 100
µM fondaparinux, 120 µM AH78 or 100 µM fondaparinux plus 120 µM AH78.

All

samples were in PBS and the fondaparinux and AH78 were pre-incubated before being
placed on the cells. After treatment, the plates were incubated at 37°C for 5 hours. The
supernatants were then transferred to another 96-well plate that had a series of known
fondaparinux standards in it to create a standard curve.

A 1.69 mM solution of 2-(4-

iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,

monosodium

salt

(WST-1) was then produced in a 0.1 M NaOH solution. A 100 µL aliquot of this WST-1
solution was added to each well to stop the assay.

The plates were covered with

Parafilm and developed at 60 °C for 60 minutes. The absorbance was measured at 584
nm using a µQuant plate reader (Bio-Tek Instruments, Inc).
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4.4 Results
4.4.1 Inhibition of Bacterial Heparinase by Platinum Drugs
4.4.1a Inhibition of Heparinase Activity
Four platinum drugs cisplatin, BBR3464, AH44 and AH78 were examined (Figure 4.3).
Of these four drugs, only the positively charged drugs (AH44, BBR3464 and AH78)
inhibit heparinase activity. BBR3464 has a charge of +4, AH44 has a charge of +6 and
AH78 has a charge of +8. As expected, AH78 inhibited heparinase activity more than
AH44.

Surprisingly, BBR3464 also inhibited heparinase activity more than AH44

(Figure 4.4).

Figure 4.4 Inhibition of heparinase activity. Pt drugs and fondaparinux were coincubated at 37 ºC for 23 hours. The heparinase was then added and incubated
for 3 hours. Error bars are ± the SEM. * denotes a p-value <0.0001.
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4.4.1b Determination of the Length of Fondaparinux-Platinum Drug PreIncubation Necessary for Heparinase Inhibition
A time course dependence study of heparinase inhibition by platinum drugs with the
substrate fondaparinux was done to investigate how long it takes for the platinum drugs
to interact with the fondaparinux.

The AH44 and AH78 instantly inhibited the

heparinase as would be expected with electrostatic binding to fondaparinux. BBR3464
instantly inhibited heparinase activity to approximately 20% of the control but the
amount of inhibition increased with time.

In fact, at 3 hours of co-incubation of

fondaparinux with BBR3464, heparinase activity was inhibited to approximately 2% of
the control (Figure 4.5). The values for all three positively charged platinum complexes
are significantly different from the untreated control at all time points investigated
(p<0.0001).

4.4.1c Heparinase Inhibition with Increasing Platinum Drug Concentration
To see how much drug was required to inhibit heparinase activity, the dose response
curves for BBR3464, AH44 and AH78 were determined (Figure 4.6). It is interesting to
note that more AH44 is required to inhibit heparinase than BBR3464 or AH78. Due to
the fact that proteins with arginine rich sequences are known to bind to heparan sulfate,
an R9-Tat protein was used as a control. At high concentrations, the R9-protein also
inhibits heparinase activity but not to the same extent as BBR3464 or AH78.
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Figure 4.5 Determination of the length of fondaparinux-platinum drug pre-incubation necessary for
heparinase inhibition. The positively charged platinum complexes were pre-incubated for the indicated
times before the addition of heparinase. The inhibition of heparinase activity due to BBR3464 increased
with time much more than was observed with AH44 and AH78. This supports the idea that BBR3464
may be able to initially bind electrostatically to fondaparinux and then covalently bind with time, whereas,
AH44 and AH78 can only bind electrostatically. Error bars are ± the SEM.
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Figure 4.6 Inhibition of heparinase due to increasing concentrations of R9-Tat protein, BBR3464, AH44
and AH78. Fondaparinux was 40 µM. The R9-Tat protein initially increases heparan sulfate cleavage
slightly but at higher concentrations, it inhibits enzyme activity. BBR3464 begins to inhibit enzyme activity
between 10 and 30 µM. AH44 begins to inhibit heparinase activity between 60 and 120 µM. AH78 begins
to inhibit heparinase activity between 10 and 30 µM. Error bars are ± the SEM.
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4.4.2 Heparanase Inhibition
The previous experiments have shown that the positively charged platinum compounds
can inhibit heparinase I activity, but can they also inhibit heparanase activity?
Heparanase is secreted from human cancer cells so a cell line could be used as a
source of heparanase.

Although it would be ideal to investigate this using the

colorimetric assay that was used for the in vitro studies with heparinase I38, this assay
method was only used in a completely in vitro system in the literature. In an effort to
modify the assay to work with cells, several conditions were investigated.

It was

determined that the medium used to grow the cells contained too many sugars that
could react with WST-1. Therefore, the incubation of the fondaparinux and AH78 had to
be done in PBS. To alter the amount of enzyme secreted, the initial number of cells
plated was examined. The concentrations of fondaparinux and AH78 were also varied
to determine the ideal concentrations. The length of time that the fondaparinux and
AH78 were exposed to the cells was also investigated.

Two cell lines were

investigated: HCT116 wt and HCT116 p53-/-. These two cell lines differ only in their
p53 status. The HCT116 p53-/- cells were chosen due to the fact that they should over
express heparanase because p53 is a negative regulator of heparanase expression.24

The finalized method involved growing the cells in a 96-well plate until they were nearly
confluent. The medium was then removed and the cells were washed with PBS. The
cells were then treated with PBS (untreated), 100 µM fondaparinux, 120 µM AH78 or
the combination of 100 µM fondaparinux and 120 µM AH78 which were mixed together
before putting it on the cells (Figure 4.7). The drug conditions were all in PBS. In the

103

HCT116 wt cells, the addition of fondaparinux increases the amount of color formation
over the baseline from the cells alone. This indicates that the fondaparinux is indeed
being cleaved by heparanse secreted from the cells. Although it is possible that there
may be other endoglycosidases that can cleave fondaparinux, the literature does not
report such endoglycosidases.

AH78 alone does not change the amount of color

formation compared to the cells alone.

However, when AH78 was added to the

fondaparinux, the amount of color formation was almost decreased to the level of the
untreated cells. This suggests that AH78 inhibited fondaparinux cleavage. The data
were normalized to the control. This gives the fold change relative to the control, which
is shown as fold control in the figure.

The difference in fold control between

fondaparinux alone and fondaparinux plus AH78 has a p-value of 5.5 x 10-7. In the
HCT116 p53-/- cells, there was a higher background from the untreated cells than was
observed with the HCT116 wt cells. Even so, with the addition of fondaparinux, more
color formation was observed. Once again, AH78 alone did not alter color formation
when compared to the untreated cells. When AH78 was added to the fondaparinux, the
amount of color produced was even closer to baseline levels than what was observed
with the HCT116 wt cells. The difference in fold control between fondaparinux alone
and fondaparinux plus AH78 has a p-value of 3.3 x 10-9.

Taken together, the data

show that AH78 inhibits fondaparinux cleavage by heparanase in both the HCT116 wt
and HCT116 p53-/- cell lines.
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Figure 4.7 Heparanse assay with cells. A) HCT116 wt. The combination of fondaparinux and AH78
reduces fondaparinux cleavage almost down to the untreated baseline. B) HCT116 p53-/-. The
combination of fondaparinux and AH78 reduces fondaparinux cleavage down to the untreated baseline.
The error bars are ± the SEM. * Denotes p-value < 0.0001
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4.5 Discussion
This research has shown that only the positively charged platinum drugs, BBR3464,
AH44 and AH78 are able to inhibit heparinase I activity.

Interestingly, BBR3464

inhibited heparinase I activity more than AH44. This is somewhat surprising because
AH44 has a charge of +6 while BBR3464 has a charge of +4. The increased inhibition
due to BBR3464 is most likely due to the chloride leaving groups, which could allow
covalent binding to the fondaparinux whereas the AH44 and AH78 can only bind
electrostatically. The results of the time course study further support this hypothesis.
The AH44 and AH78 instantly inhibited the heparinase, as would be expected with
electrostatic binding to fondaparinux. The fact that BBR3464 had an initial inhibition
that increased over the course of 3-hours, supports the hypothesis that BBR3464 has
an initial electrostatic interaction with fondaparinux followed by covalent binding over
time.

The in vitro colorimetric assay used to measure heparinase I inhibition was successfully
modified to investigate heparanase inhibition in cell culture. These studies showed that
although the cells secreted components that would react with WST-1, the addition of
fondaparinux would increase the amount of color formation, presumably due to
fondaparinux cleavage.

Furthermore, the addition of AH78 with the fondaparinux,

decreased the color formation almost to cellular baseline. This shows that AH78 can
inhibit heparanase activity in a cellular environment.
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In conclusion, the positively charged platinum-based chemotherapeutics can inhibit
fondaparinux cleavage by both heparinase I and heparanase. The enzyme inhibition
with respect to AH44 and AH78 was charge dependent. BBR3464 inhibited enzyme
activity more than AH44 despite being less positively charged. Time course studies
showed

that

the

interaction

between

the

positively

charged

platinum-based

chemotherapeutics and the fondaparinux is instantaneous. It further suggested that
BBR3464 may have an initial electrostatic binding followed by covalent binding whereas
AH44 and AH78 can only bind electrostatically. In total, the results prove the concept
that positively charged platinum-based chemotherapeutics can inhibit heparanase
activity and may be able to reduce tumor angiogenesis and metastasis.

To confirm that BBR3464 covalently binds to fondaparinux, mass spectrometry studies
are currently underway. To gain insight into the reaction, isothermal titration calorimetry
experiments could also be performed. As understanding of the interaction between the
positively charged platinum complexes and heparan sulfate proteoglycans is gained,
compounds with a higher affinity for heparan sulfate could be designed.

These

compounds would be able to elicit the same heparanase inhibition at lower doses.

In the future, the functional relevance of the findings discussed in this chapter need to
be investigated using angiogenesis and metastasis assays.

Angiogenesis and

metastasis could be investigated using angiogenesis bead assays or by doing a flank
tumor model in mice. Although functional relevance remains to be proven, this work
does suggest a new way to target heparanase activity in cancer patients.
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Appendix 1
Effect of Imipramine on BBR3464 Cytotoxicity and the
Effect of Clomipramine on the Cytotoxicity of the
Platinum Drugs
A.1.1 Abstract
In continuation of the work discussed in chapters two and three, the percent apoptosis
due

to

the

cationic

trinuclear

agent

BBR3464

[{trans-PtCl(NH3)2}2µ-(trans-

Pt(NH3)2(H2N(CH2)6NH2)2)]4+ was investigated in the presence and absence of
imipramine in HCT116 wt cells. It was found that imipramine inhibits the cytotoxicity of
BBR3464. Another tricylic antidepressant, clomipramine, was also investigated with
cisplatin, oxaliplatin, carboplatin and BBR3464.

Clomipramine augmented the

cytotoxicity of cisplatin and oxaliplatin. Although clomipramine appears to augment the
cytotoxicity of carboplatin and BBR3464, clomipramine is far more toxic than the other
antidepressants used and the observed augmentation was not significantly different
from the cytotoxicity due to clomipramine alone.

A.1.2 Introduction
The work discussed in this appendix is a continuation of the work discussed in chapters
two and three. Given how much desipramine enhanced the cytotoxicity of the cationic
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tri-nuclear agent BBR3464 [{trans-PtCl(NH3)2}2µ-(trans-Pt(NH3)2(H2N(CH2)6NH2)2)]4+, it
was important to investigate how specific the effect was to desipramine. To this end,
the percent apoptosis due to BBR3464 was investigated in the presence of two other
tricyclic antidepressants, imipramine and clomipramine (Figure A.1.1). As shown in
Figure 3.1, imipramine and desipramine differ by one methyl group. As can be seen in
Figure A.1.1 clomipramine differs from imipramine by the addition of one chloride group.
Although these structural differences are minor, it is important to determine how they
effect the observed augmentation of cytotoxicity due to platinum anti-cancer drugs. To
further investigate this, the percent apoptosis due to cisplatin, oxaliplatin and carboplatin
were also investigated in the presence and absence of clomipramine.

Figure A.1.1 Structures of imipramine and clomipramine.
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A.1.3 Materials and Methods
A.1.3.1 Materials
HCT 116 human colon carcinoma cells were a gift from Bert Vogelstein (Johns Hopkins
University, Baltimore MD). McCoy’s 5a Medium Modified, RPMI, Fetal bovine serum
(FBS), L-glutamine, penicillin, streptomycin, HEPES buffer and sodium pyruvate were
all purchased from Biofluids (Rockville, MD).

A.1.3.2 Cell Systems and Culture Conditions
HCT116 wt cells were used. The medium used types was RPMI 1640 with 10% fetal
bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillinin, 100 g/mL streptomycin, 10
mmol/L HEPES buffer and 1 mmol/L sodium pyruvate. (cRPMI, all from Biofluids,
Rockville, MD). The cells were cultured in 175 cm2 Cell Star tissue culture flasks from
Greiner Bio-One (Frickenhausen, Germany) in an incubator with 5% CO2 and humidified
air.

A.1.3.3 Apoptosis Studies
Cells were cultured in 6-well plates with 7.0 x 104 cells per well. A 3 mL aliquot of
medium was put in each well. Cells were treated for 24 hours, 48 hours or 72 hours
with these conditions: untreated, platinum drug by itself, antidepressant by itself, and
platinum drug plus antidepressant. The platinum drugs were added to the medium after
a one-hour treatment period with the antidepressant. At the time points, all cells
(adherent and non-adherent) were collected. As described previously, the cells were
fixed with an ethanol/fetal bovine serum solution and stained with a propidium
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iodide/RNAse A solution.1 The samples were analyzed for subdiploid DNA content
using a Becton Dickinson FACScan flow cytometer (BD Biosciences, San Jose, CA).
This protocol allows the detection of intact versus fragmented DNA, which allows cell
cycle analysis.
A.1.4 Results
Imipramine significantly inhibited the cytotoxicity of BBR3464 at 24, 48 and 72 hours. At
24 hours, BBR3464 caused 13% apoptosis while the combination of BBR3464 plus
imipramine only caused 7% apoptosis with a p-value of 0.05. At 48 hours, BBR3464
alone caused 19% apoptosis while BBR3464 plus imipramine only caused 9%
apoptosis. This difference has a p-value of 0.005. At 72 hours, BBR3464 alone caused
24% apoptosis while the combination of BBR3464 and imipramine only caused 12%
apoptosis with a p-value of 0.02 (Figure A.1.2).
Another tricyclic antidepressant, clomipramine was also investigated.

Clomipramine

augmented the cytotoxicity of both cisplatin and oxaliplatin. At 24 hours, cisplatin alone
caused 8% apoptosis while the combination of cisplatin plus clomipramine caused 17%
apoptosis with a p-value of 0.05. At 48 hours, cisplatin caused 42% apoptosis while
cisplatin plus clomipramine caused 44% apoptosis.

Although there is only a 2%

difference between these two values, it is a statistically significant difference and has a
p-value of 1.4 x 10-8. At 72 hours, the percent apoptosis caused by cisplatin increased
to 48% while the percent apoptosis due to cisplatin plus clomipramine increased to
95%. This difference has a p-value of 1.1 x 10-9 (Figure A.1.3 A).
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Figure A.1.2 Imipramine inhibits the cytotoxicity of BBR3464 in HCT116 wt cells. Error bars are ± the
SEM. BBR3464 was 10 µM and imipramine was 40 µM.
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Clomipramine also enhances the cytotoxicity of oxaliplatin.

At 24 hours, oxaliplatin

alone caused 4% apoptosis while the combination of oxaliplatin plus clomipramine
caused 17% apoptosis.

This difference has a p-value of 0.0005.

At 48 hours,

oxaliplatin alone caused 22% apoptosis whereas oxaliplatin plus clomipramine caused
44% apoptosis with a p-value of 3.1 x 10-8.

At 72 hours, oxaliplatin caused 28%

apoptosis while the combination with clomipramine caused 67% apoptosis with a pvalue of 5.4 x 10-6 (Figure A.1.3 B).

The results are different with carboplatin and BBR3464. In both cases, the combination
of the platinum drug with clomipramine is in fact significantly different from the percent
apoptosis due to the platinum drug alone at all three time points investigated.
Unfortunately, clomipramine by itself is quite a bit more cytotoxic than the other
antidepressants that were investigated in Chapter 3. So although the combination of
platinum drugs with clomipramine is significantly different from the percent apoptosis
due to the drug alone, it is not significantly different from the percent apoptosis due to
clomipramine alone (Figure A.1.3 C and D).
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Figure A.1.3 Effect of clomipramine on the cytotoxicity of cisplatin, oxaliplatin, carboplatin and BBR3464
in HCT116 wt cells. Error bars are ± the SEM. Cisplatin was 10 µM, oxaliplatin was 10 µM, Carboplatin
was 10 µM, BBR3464 was 10 µM and clomipramine was 40 µM.

A.1.5 Discussion
This work has demonstrated that imipramine augments the cytotoxicity of BBR3464
although the increase is not as much as what was observed with desipramine (Figure
2.2). This is further evidence that desipramine and imipramine do something different in
the cells.
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Although clomipramine only differs from imipramine by one chloride group the results
were quite different. Clomipramine augmented the cytotoxicity of both cisplatin and
oxaliplatin

whereas

imipramine

augmented

cisplatin

and

inhibited

oxaliplatin.

Clomipramine did not enhance the cytotoxicity of BBR3464 or carboplatin. Due to the
cytotoxicity of clomipramine, even at lower doses, further work with this antidepressant
was abandoned.
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